MYELOF
MCID: MYL005
MIFTS: 67

Myelofibrosis (MYELOF)

Categories: Blood diseases, Cancer diseases, Genetic diseases, Rare diseases

Aliases & Classifications for Myelofibrosis

MalaCards integrated aliases for Myelofibrosis:

Name: Myelofibrosis 56 12 74 52 73 36 29 54 6 15 37 39 71
Primary Myelofibrosis 12 52 25 58 54 43 17 71
Agnogenic Myeloid Metaplasia 12 52 25 58 73 54
Idiopathic Myelofibrosis 52 25 58 73 54
Myelofibrosis with Myeloid Metaplasia 25 58 73 6
Myeloid Metaplasia 52 25 54 71
Osteomyelofibrosis 58 71 32
Myelofibrosis with Myeloid Metaplasia, Somatic 56 13
Megakaryocytic Myelosclerosis 12 71
Myelosclerosis 12 73
Agnogenic Myeloid Metaplasia with Myelofibrosis 73
Myelosclerosis with Myeloid Metaplasia 73
Chronic Idiopathic Myelofibrosis 25
Myelofibrosis, Somatic 56
Bone Marrow Fibrosis 12
Aleukemic Myelosis 12
Myelof 73
Ammm 73
Mmm 73

Characteristics:

Orphanet epidemiological data:

58
primary myelofibrosis
Prevalence: 1-9/100000 (Europe); Age of onset: Adult;

OMIM:

56
Inheritance:
somatic mutation

Miscellaneous:
onset first weeks of life


HPO:

31

Classifications:

Orphanet: 58  
Rare haematological diseases


Summaries for Myelofibrosis

Genetics Home Reference : 25 Primary myelofibrosis is a condition characterized by the buildup of scar tissue (fibrosis) in the bone marrow, the tissue that produces blood cells. Because of the fibrosis, the bone marrow is unable to make enough normal blood cells. The shortage of blood cells causes many of the signs and symptoms of primary myelofibrosis. Initially, most people with primary myelofibrosis have no signs or symptoms. Eventually, fibrosis can lead to a reduction in the number of red blood cells, white blood cells, and platelets. A shortage of red blood cells (anemia) often causes extreme tiredness (fatigue) or shortness of breath. A loss of white blood cells can lead to an increased number of infections, and a reduction of platelets can cause easy bleeding or bruising. Because blood cell formation (hematopoiesis) in the bone marrow is disrupted, other organs such as the spleen or liver may begin to produce blood cells. This process, called extramedullary hematopoiesis, often leads to an enlarged spleen (splenomegaly) or an enlarged liver (hepatomegaly). People with splenomegaly may feel pain or fullness in the abdomen, especially below the ribs on the left side. Other common signs and symptoms of primary myelofibrosis include fever, night sweats, and bone pain. Primary myelofibrosis is most commonly diagnosed in people aged 50 to 80 but can occur at any age.

MalaCards based summary : Myelofibrosis, also known as primary myelofibrosis, is related to myeloproliferative neoplasm and megakaryocytic leukemia. An important gene associated with Myelofibrosis is MPL (MPL Proto-Oncogene, Thrombopoietin Receptor), and among its related pathways/superpathways are JAK-STAT signaling pathway and Response to elevated platelet cytosolic Ca2+. The drugs Parathyroid hormone and Calcium have been mentioned in the context of this disorder. Affiliated tissues include bone, myeloid and bone marrow, and related phenotypes are splenomegaly and hepatomegaly

Disease Ontology : 12 A myeloid neoplasm that is located in the bone marrow which results in bone marrow being replaced by fibrous (scar) tissue.

NIH Rare Diseases : 52 Myelofibrosis is a disorder of the spongy tissue inside the bone (bone marrow) that contains the stem cells that will form blood cells . In myelofibrosis, the bone marrow is replaced by fibrous (scar) tissue. When the bone marrow is scarred, it cannot make enough blood cells. This leads to anemia , weakness, fatigue, and often, swelling of the liver and spleen. The disorder occurs when blood stem cells develop somatic mutations in the JAK2 , MPL , CALR , and TET2 genes . Other genes may also be involved. The disorder is generally not inherited because this type of mutation does not affect the reproductive cells (sperm and egg) only certain cells of the body (somatic). Although myelofibrosis can occur at any age, it typically develops after the age of 50 years. In most cases, myelofibrosis gets progressively worse. Treatment is aimed at relieving signs and symptoms and may include medications, blood transfusions, chemotherapy , radiation therapy , and surgery. Bone marrow or stem cell transplant may improve symptoms, and may cure the disease.

KEGG : 36 Myelofibrosis (MF), one of the three classic Philadelphia-chromosome-negative myeloproliferative neoplasms (MPNs), is characterized by symptoms mainly derived from anemia and splenomegaly and constitutional symptoms and associated with a median survival around 6 years. Most MPN patients harbor an acquired mutation in the hemopoietic cells, the V617F mutation, located in the pseudokinase domain of the JAK2 gene. This mutation results in a gain of function, i.e., in the constitutive activation of the JAK-STAT pathway, which plays an important role in the proliferation, differentiation, and survival of the hemopoietic cells, as well as in the immune function. Besides, a minority of patients with MF (most of them negative for the JAK2 mutation) harbor other JAK-STAT-activating mutation, the MPL mutation, in the gene of the receptor of the thrombopoietin. Recently, mutations in the CALR gene have been described in 86% of cases with primary MF that are negative for JAK2 or MPL mutations. CALR mutation also showed cytokine independent growth of cells due to activation of STAT5 involved with the JAK-STAT pathway but its exact role in MPN remains to be clarified.

UniProtKB/Swiss-Prot : 73 Myelofibrosis: A disorder characterized by replacement of the bone marrow by fibrous tissue, occurring in association with a myeloproliferative disorder. Clinical manifestations may include anemia, pallor, splenomegaly, hypermetabolic state, petechiae, ecchymosis, bleeding, lymphadenopathy, hepatomegaly, portal hypertension.
Myelofibrosis with myeloid metaplasia: A chronic myeloproliferative disorder characterized by replacement of the bone marrow by fibrous tissue, extramedullary hematopoiesis, anemia, leukoerythroblastosis and hepatosplenomegaly.

Wikipedia : 74 Primary myelofibrosis is a relatively rare bone marrow/blood cancer. It is currently classified as a... more...

More information from OMIM: 254450

Related Diseases for Myelofibrosis

Diseases related to Myelofibrosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 624)
# Related Disease Score Top Affiliating Genes
1 myeloproliferative neoplasm 33.4 U2AF1 THPO TET2 SH2B3 MPL KIT
2 megakaryocytic leukemia 33.3 U2AF1 THPO JAK2 GATA1
3 polycythemia vera 33.3 THPO TET2 MPL KIT JAK2 HMGA2
4 splenomegaly 32.6 MPL JAK2 EPO
5 essential thrombocythemia 32.5 U2AF1 THPO TET2 SH2B3 MPL MIR223
6 polycythemia 32.3 THPO TET2 SH2B3 MPL JAK2 EPO
7 pancytopenia 32.0 U2AF1 THPO MPL MPIG6B KIT EPO
8 thrombocytosis 32.0 U2AF1 THPO TET2 MPL JAK2 EPO
9 thrombocytopenia 32.0 U2AF1 THPO MPL MPIG6B JAK2 GATA1
10 leukemia 31.8 U2AF1 THPO MPL KIT JAK2 CDKN2B-AS1
11 acute leukemia 31.8 THPO KIT JAK2 GATA1
12 deficiency anemia 31.7 U2AF1 THPO SH2B3 MPL JAK2 GATA1
13 neutropenia 31.7 THPO MPL EPO CD177
14 myelodysplastic syndrome 31.6 U2AF1 THPO TET2 MPL MEG3 KIT
15 refractory anemia 31.4 TET2 MPL EPO
16 chronic myelomonocytic leukemia 31.4 U2AF1 TET2 MPL KIT JAK2 CALR
17 myeloma, multiple 31.4 U2AF1 MEG3 KIT JAK2 FGF2 EPO
18 mastocytosis 31.4 TET2 KIT JAK2
19 systemic mastocytosis 31.3 TET2 KIT JAK2
20 hemoglobinuria 31.2 THPO MPL EPO
21 aplastic anemia 31.1 U2AF1 THPO TET2 MPL GATA1 FGF2
22 budd-chiari syndrome 31.1 MPL JAK2 CALR
23 acquired polycythemia 31.0 MPL JAK2 EPO
24 portal vein thrombosis 30.9 MPL JAK2 CALR
25 hypersplenism 30.9 THPO EPO BMP6
26 erythroleukemia, familial 30.8 GATA1 EPO
27 chronic neutrophilic leukemia 30.8 U2AF1 TET2 JAK2 CALR
28 chronic eosinophilic leukemia 30.8 U2AF1 TET2 KIT JAK2
29 myelophthisic anemia 30.7 U2AF1 TET2 SH2B3 MPL JAK2 EPO
30 splenic sequestration 30.6 THPO MPL EPO
31 thrombocythemia 1 30.6 THPO SH2B3 MPL CALR
32 erythrocytosis, familial, 1 30.5 SH2B3 JAK2 EPO
33 myelodysplastic/myeloproliferative neoplasm 30.5 U2AF1 TET2 JAK2
34 chronic leukemia 30.5 U2AF1 TET2 KIT JAK2
35 indolent systemic mastocytosis 30.5 U2AF1 TET2 KIT
36 diamond-blackfan anemia 30.5 U2AF1 THPO MPL JAK2 GATA1 EPO
37 leukemia, chronic myeloid 30.4 U2AF1 THPO MPL MIR223 MEG3 KIT
38 blood platelet disease 30.4 U2AF1 THPO MPL KIT JAK2 GATA1
39 primary polycythemia 30.4 U2AF1 THPO TET2 SH2B3 MPL JAK2
40 leukemia, acute myeloid 30.3 WT1-AS U2AF1 THPO TET2 MPL MIR223
41 leukemia, acute lymphoblastic 30.3 U2AF1 THPO MPL MIR223 KIT JAK2
42 glioma 30.1 MIR146B MEG3 FGF2 CDKN2B-AS1
43 acquired von willebrand syndrome 30.0 U2AF1 JAK2
44 hematologic cancer 30.0 U2AF1 THPO MPL MIR223 MIR146B KIT
45 leukemia, chronic lymphocytic 29.9 U2AF1 THPO MIR223 KIT JAK2
46 acute panmyelosis with myelofibrosis 12.8
47 thrombocytopenia, anemia, and myelofibrosis 12.5
48 cellular phase chronic idiopathic myelofibrosis 12.3
49 thrombocytopenia 6 12.1
50 gray platelet syndrome 11.9

Graphical network of the top 20 diseases related to Myelofibrosis:



Diseases related to Myelofibrosis

Symptoms & Phenotypes for Myelofibrosis

Human phenotypes related to Myelofibrosis:

58 31 (show all 38)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 splenomegaly 58 31 frequent (33%) Frequent (79-30%) HP:0001744
2 hepatomegaly 58 31 frequent (33%) Frequent (79-30%) HP:0002240
3 fatigue 58 31 frequent (33%) Frequent (79-30%) HP:0012378
4 anemia 58 31 frequent (33%) Frequent (79-30%) HP:0001903
5 pallor 58 31 frequent (33%) Frequent (79-30%) HP:0000980
6 thrombocytopenia 58 31 frequent (33%) Frequent (79-30%) HP:0001873
7 hepatosplenomegaly 58 31 frequent (33%) Frequent (79-30%) HP:0001433
8 abnormal megakaryocyte morphology 58 31 frequent (33%) Frequent (79-30%) HP:0012143
9 portal hypertension 58 31 occasional (7.5%) Occasional (29-5%) HP:0001409
10 pancytopenia 58 31 occasional (7.5%) Occasional (29-5%) HP:0001876
11 venous thrombosis 58 31 occasional (7.5%) Occasional (29-5%) HP:0004936
12 anorexia 58 31 occasional (7.5%) Occasional (29-5%) HP:0002039
13 easy fatigability 58 31 occasional (7.5%) Occasional (29-5%) HP:0003388
14 thrombocytosis 58 31 occasional (7.5%) Occasional (29-5%) HP:0001894
15 leukocytosis 58 31 occasional (7.5%) Occasional (29-5%) HP:0001974
16 petechiae 58 31 occasional (7.5%) Occasional (29-5%) HP:0000967
17 arterial thrombosis 58 31 occasional (7.5%) Occasional (29-5%) HP:0004420
18 lymphadenopathy 58 31 occasional (7.5%) Occasional (29-5%) HP:0002716
19 low-grade fever 58 31 occasional (7.5%) Occasional (29-5%) HP:0011134
20 extramedullary hematopoiesis 58 31 occasional (7.5%) Occasional (29-5%) HP:0001978
21 poikilocytosis 58 31 occasional (7.5%) Occasional (29-5%) HP:0004447
22 bone marrow hypercellularity 58 31 occasional (7.5%) Occasional (29-5%) HP:0031020
23 ecchymosis 58 31 occasional (7.5%) Occasional (29-5%) HP:0031364
24 flank pain 58 31 occasional (7.5%) Occasional (29-5%) HP:0030157
25 cachexia 58 31 very rare (1%) Very rare (<4-1%) HP:0004326
26 increased lactate dehydrogenase activity 58 31 very rare (1%) Very rare (<4-1%) HP:0025435
27 hemangioma 58 31 very rare (1%) Very rare (<4-1%) HP:0001028
28 hematological neoplasm 58 31 very rare (1%) Very rare (<4-1%) HP:0004377
29 fever 58 31 Occasional (29-5%) HP:0001945
30 purpura 58 31 Occasional (29-5%) HP:0000979
31 abnormal bleeding 58 Occasional (29-5%)
32 abnormal thrombosis 58 Occasional (29-5%)
33 abnormality of blood and blood-forming tissues 58 Frequent (79-30%)
34 abnormality of bone marrow cell morphology 58 Very frequent (99-80%)
35 autoimmune antibody positivity 58 Excluded (0%)
36 constitutional symptom 58 Frequent (79-30%)
37 myeloproliferative disorder 31 HP:0005547
38 myelofibrosis 31 HP:0011974

Symptoms via clinical synopsis from OMIM:

56
Hematology:
myeloproliferative disease
reduced hemopoiesis
generalized bone marrow fibrosis
no hemophagocytosis

Clinical features from OMIM:

254450

MGI Mouse Phenotypes related to Myelofibrosis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.36 CD177 EPO FGF2 GATA1 JAK2 KIT

Drugs & Therapeutics for Myelofibrosis

Drugs for Myelofibrosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 331)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Parathyroid hormone Approved, Investigational Phase 4 9002-64-6
2
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
3
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
4
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
5
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 6221 5280795
6
Lactitol Investigational Phase 4 585-86-4, 585-88-6 493591
7 Hormones Phase 4
8 Vitamins Phase 4
9 Trace Elements Phase 4
10 Micronutrients Phase 4
11 Nutrients Phase 4
12 Mitogens Phase 4
13 Calcium, Dietary Phase 4
14 Endothelial Growth Factors Phase 4
15 Ergocalciferols Phase 4
16 Vitamin D2 Phase 4
17 Angiogenesis Inducing Agents Phase 4
18 Calciferol Phase 4
19
Tin Phase 4 7440-31-5
20 Tin Fluorides Phase 4
21 Fluorides Phase 4
22 Cariostatic Agents Phase 4
23
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
24
Acyclovir Approved Phase 3 59277-89-3 2022
25
Ribavirin Approved Phase 3 36791-04-5 37542
26
Palivizumab Approved, Investigational Phase 3 188039-54-5
27
Dalteparin Approved Phase 3 9005-49-6
28
Captopril Approved Phase 3 62571-86-2 44093
29
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
30
Itraconazole Approved, Investigational Phase 3 84625-61-6 55283
31
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
32
Carboplatin Approved Phase 2, Phase 3 41575-94-4 10339178 498142 38904
33
Aspirin Approved, Vet_approved Phase 3 50-78-2 2244
34
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
35
Caspofungin Approved Phase 3 162808-62-0, 179463-17-3 468682 2826718
36
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
37
Peginterferon alfa-2a Approved, Investigational Phase 3 198153-51-4 5360545
38
Peginterferon alfa-2b Approved Phase 3 215647-85-1, 99210-65-8
39
Anagrelide Approved Phase 3 68475-42-3 2182
40
Cytarabine Approved, Experimental, Investigational Phase 3 147-94-4, 65-46-3 6253
41
Hydroxyurea Approved Phase 3 127-07-1 3657
42
Mercaptopurine Approved Phase 3 50-44-2 667490
43
Danazol Approved Phase 3 17230-88-5 28417
44
Norgestimate Approved, Investigational Phase 3 35189-28-7 6540478
45
Moxifloxacin Approved, Investigational Phase 3 151096-09-2, 354812-41-2 152946
46
Polyestradiol phosphate Approved Phase 3 28014-46-2
47
Estradiol Approved, Investigational, Vet_approved Phase 3 50-28-2 5757
48
Ethinyl Estradiol Approved Phase 3 57-63-6 5991
49
St. John's Wort Approved, Investigational, Nutraceutical Phase 3 84082-80-4
50
Ginseng Approved, Investigational, Nutraceutical Phase 3 50647-08-0

Interventional clinical trials:

(showing 469, show less)
# Name Status NCT ID Phase Drugs
1 A UK Open-label, Multicentre, Exploratory Phase II Study of INC424 for Patients With Primary Myelofibrosis (PMF) or Post Polycythaemia Myelofibrosis (PPV MF) or Post Essential Thrombocythaemia Myelofibrosis (PET-MF) Completed NCT01558739 Phase 4 INC424
2 The Study of Efficacy and Safety of Calcium Sensing Receptor in Chronic Dialysis Patients Completed NCT02056730 Phase 4 calcium sensing receptor agonist
3 The Effects of Vitamin D Supplementation on Transforming Growth Factor-beta1 and Vascular Endothelial Growth Factor in Vitamin D-Deficient Women With Polycystic Ovary Syndrome: A Randomized Placebo-Controlled Trial Completed NCT02460380 Phase 4 Vitamin D3
4 An Open Label, Multi-center, Phase IV Rollover Protocol for Patients Who Have Completed a Global Novartis or Incyte Sponsored Ruxolitinib (INC424) or Ruxolitinib and Panobinostat (LBH589) Combination Study and Are Judged by the Investigator to Benefit From Continued Treatment Recruiting NCT02386800 Phase 4 Ruxolitinib;Panobinostat
5 Rate of Prolonged Response After Stopping Thrombopoietin-receptor Agonists Treatment in Immune Thrombocytopenia: a Prospective Multicenter Open Study Recruiting NCT03119974 Phase 4 Tpo-RA discontinuation
6 A Randomized Double-Blind Controlled Trial of Ketamine Versus Placebo in Conjunction With Best Pain Management in Neuropathic Pain in Cancer Patients Unknown status NCT01316744 Phase 3 ketamine hydrochloride
7 A Multicenter, Open-label Clinical Study of the JAK Inhibitor Ruxolitinib (INC424) in Patients With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis Completed NCT02087059 Phase 3 Ruxolitinib
8 An Open-label, Multicenter, Expanded Access Study of INC424 for Patients With Primary Myelofibrosis (PMF) or Post Polycythemia Myelofibrosis (PPV MF) or Post-essential Thrombocythemia Myelofibrosis (PET-MF). Completed NCT01493414 Phase 3 INC424
9 A Phase III Multicenter Study of Cytomegalovirus Prophylaxis With Valacyclovir for the Prevention of Serious Fungal and Bacterial Infections Among Cytomegalovirus Seronegative Recipients of Cytomegalovirus Seropositive Sx Stem Cell Transplants Completed NCT00045292 Phase 3 acyclovir;acyclovir sodium;valacyclovir
10 A Randomized Double-Blind Placebo-Controlled Phase III Study To Evaluate The Safety And Efficacy Of Palivizumab Combined With Aerosolized Ribavirin Compared To Ribavirin Alone To Treat RSV Pneumonia In Patients With Bone Marrow Transplants (BMT) Completed NCT00014391 Phase 3 ribavirin
11 A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Fragmin (5,000 IU Subcutaneously) in Preventing Catheter-Related Complications When Given Daily to Cancer Patients With Central Venous Catheters Completed NCT00006083 Phase 3 Fragmin
12 Phase III Study of Captopril in Patients Undergoing Autologous Bone Marrow/Stem Cell Transplantation Completed NCT00004230 Phase 3 captopril;cyclophosphamide
13 A Randomized, Comparative Study of Itraconazole Versus Fluconazole for Prevention of Aspergillus Infections in Peripheral Blood Stem Cell and Marrow Transplant Recipients Completed NCT00003883 Phase 3 fluconazole;itraconazole
14 A Phase III Double-Blind Equivalence Study of Two Different Formulations of Slow-Release Morphine Followed by a Randomization Between Dextromethorphan or Placebo Plus Statex SR for Chronic Cancer Pain Relief in Terminally Ill Patients Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
15 A Randomized Study of Ruxolitinib Tablets Compared to Best Available Therapy in Subjects With Primary Myelofibrosis, Post-Polycythemia Vera-Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis Completed NCT00934544 Phase 3 Ruxolitinib;Best Available Therapy (BAT)
16 A Randomized, Double-blind, Placebo-controlled Study of the JAK Inhibitor INCB018424 Tablets Administered Orally to Subjects With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis Completed NCT00952289 Phase 3 Ruxolitinib;Placebo
17 A Phase-3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Compare Efficacy and Safety of Pomalidomide in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis and Red Blood Cell-Transfusion-Dependence Completed NCT01178281 Phase 3 Pomalidomide 0.5 mg;Placebo;Pomalidomide
18 A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study of SAR302503 in Patients With Intermediate-2 or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis With Splenomegaly Completed NCT01437787 Phase 3 SAR302503;Placebo
19 A Study to Provide Expanded Access of (Exjade®) Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload From Blood Transfusions Who Cannot Adequately be Treated With Other Locally Approved Iron Chelators Completed NCT00235391 Phase 3 Deferasirox
20 A Randomized Multicentre Study Comparing G-CSF Mobilized Peripheral Blood and G-CSF Stimulated Bone Marrow in Patients Undergoing Matched Sibling Transplantation for Hematologic Malignancies Completed NCT00438958 Phase 3
21 Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea Therapy in the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET) Completed NCT01259856 Phase 3 PEGASYS;Hydroxyurea;Aspirin
22 INSPIRE: An Internet-based RCT for Long-term Survivors of Hematopoietic Stem Cell Transplantation Completed NCT00799461 Phase 3
23 Randomized Placebo Controlled Double Blind Study of Restasis Versus Placebo in Primary Prevention of Ocular GVHD After Allogeneic Stem Cell Transplantation Completed NCT00755040 Phase 3 cyclosporine ophthalmic emulsion
24 HSCT-CHESS to Enhance Hematopoietic Transplant Recovery Completed NCT00782145 Phase 3
25 Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer Completed NCT00006348 Phase 3 ondansetron
26 Allogeneic Blood or Marrow Transplantation for Hematologic Malignancy and Aplastic Anemia Completed NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
27 Music Video and Adolescent/Young Adult Resilience During Transplant Completed NCT00305851 Phase 3
28 Does Hypericum Reduce Fatigue in Cancer Patients on Chemotherapy? A Randomized, Double-Blind, Placebo-Controlled Clinical Trial Completed NCT00005805 Phase 3
29 Preparatory Aid to Improve Decision Making About Cancer Clinical Trials (PRE-ACT) Completed NCT00750009 Phase 3
30 A Multicenter, Double-Blind, Randomized, Comparative Study To Evaluate The Safety, Tolerability, And Efficacy Of MK-0991 Versus (Amphotericin B) Liposome For Injection As Empirical Therapy In Patients With Persistent Fever And Neutropenia Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
31 A Strategic Study to Determine the Optimal Moment to Initiate Systemic Antifungal Therapy With Ambisome in Granulocytopenic Cancer Patients With Unexplained Fever Refractory to Empirical Antibacterials Completed NCT00003938 Phase 3 liposomal amphotericin B
32 The Use of American Ginseng (Panax Quinquefolius) to Improve Cancer-Related Fatigue: A Randomized, Double-Blind, Placebo-Controlled Phase III Study Completed NCT00719563 Phase 3 American ginseng
33 Phase III Randomized Trial of an Opioid Titration Order Sheet Compared to Standard of Care in Patients With Cancer Related Pain. Completed NCT00666211 Phase 3
34 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
35 A Phase 3b, Multicenter, Single-arm, Open-label Safety AND Efficacy Study of Fedratinib in Subjects With DIPSS-Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis Recruiting NCT03755518 Phase 3 FEDRATINIB
36 A Phase 3, Multicenter, Open-label, Randomized Study to Evaluate the Efficacy and Safety of Fedratinib Compared to Best Available Therapy (BAT) in Subjects With DIPSS (Dynamic International Prognostic Scoring System)-Intermediate or High-risk Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), or Post-essential Thrombocythemia Myelofibrosis (Post-ET MF) and Previously Treated With Ruxolitinib Recruiting NCT03952039 Phase 3 FEDRATINIB;Best Available Therapy (BAT)
37 A Phase 3b, Open Label, Single-arm Rollover Study to Evaluate Long Term Safety in Subjects Who Have Participated in Other Luspatercept (Ace-536) Clinical Trials. Recruiting NCT04064060 Phase 3 Luspatercept
38 A Phase 3, Randomized, Double-blind Active-controlled Study Evaluating Momelotinib vs. Ruxolitinib in Subjects With Primary Myelofibrosis (PMF) or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF) Active, not recruiting NCT01969838 Phase 3 Momelotinib;Ruxolitinib;Placebo to match momelotinib;Placebo to match ruxolitinib
39 A Phase 3, Randomized Study To Evaluate the Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis Who Were Treated With Ruxolitinib Active, not recruiting NCT02101268 Phase 3 Momelotinib;Best Available Therapy (BAT)
40 A Randomized, Double-Blind, Phase 3 Study of Momelotinib vs Danazol in Symptomatic, Anemic Subjects With Previously JAKi Treated Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post Essential Thrombocythemia Myelofibrosis Active, not recruiting NCT04173494 Phase 3 Momelotinib;Danazol;Placebo to match momelotinib;Placebo to match danazol
41 Eltrombopag for the Management of Thrombocytopenia Associated With Tyrosine Kinase Therapy in Patients With Chronic Myeloid Leukemia (CML) and Myelofibrosis (MF) Active, not recruiting NCT01428635 Phase 2, Phase 3 Eltrombopag Olamine
42 Danish Study of Low-dose Interferon Alpha Versus Hydroxyurea in the Treatment of Philadelphia Chromosome Negative (Ph-)Chronic Myeloid Neoplasms. Active, not recruiting NCT01387763 Phase 3 PegIntron;Pegasys;PegIntron;Pegasys;Hydrea
43 A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis Terminated NCT01773187 Phase 3 Pacritinib;Best Available Therapy
44 A Randomized Study to Evaluate The Efficacy of Mycophenolate Mofetil Added to The Systemic Immunosuppressive Regimen First Used For Treatment of Chronic Graft-Versus-Host Disease Terminated NCT00089141 Phase 3 mycophenolate mofetil;placebo
45 A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis Terminated NCT02055781 Phase 3 Pacritinib;Best Available Therapy
46 A Randomized, Double Blind, Placebo-controlled, Multicenter, Phase III Study Investigating the Efficacy and Safety of Ruxolitinib in Early Myelofibrosis Patients With High Molecular Risk Mutations Terminated NCT02598297 Phase 3 Ruxolitinib;Ruxolitinib Placebo
47 Randomized, Double Blinded, Placebo-Controlled Trial of Antibacterial Prophylaxis for the Prevention of Bacterial Infections in the Post-Engraftment Phase After Allogeneic Hematopoeitic Stem Cell Transplantation Terminated NCT00324324 Phase 3 moxifloxacin hydrochloride;Placebo
48 A Phase I/II Open Label Study of LBH589, a Novel Histone Deacetylase Inhibitor (HDACi), in Patients With Primary Myelofibrosis (PMF) and Post-polycythemia/Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF) Unknown status NCT01298934 Phase 1, Phase 2 LBH589
49 A Multicenter, Open Label Phase I/II Study of CEP-701 (Lestaurtinib) in Adults With Myelofibrosis Unknown status NCT00668421 Phase 1, Phase 2 CEP-701 (Lestaurtinib)
50 A Multiinstitutional Trial To Evaluate The Prophylactic Use Of NASA-Developed Light Emitting Diodes For The Prevention Of Oral Mucositis In Bone Marrow Transplant Patients Unknown status NCT00036712 Phase 2
51 A Phase II Study of MK-0683 in Patients With Polycythaemia Vera and Essential Thrombocythaemia. Unknown status NCT00866762 Phase 2 HDAC inhibitor (MK-0683)
52 A Phase I/II Trial of Ruxolitinib in Chronic Lymphocytic Leukemia Patients at Risk for Progression on Ibrutinib Unknown status NCT02912754 Phase 1, Phase 2 ruxolitinib;ibrutinib
53 A Phase II Study of Gleevec (Imatinib Mesylate) In Patients With BCR-Negative Myeloproliferative Disorders Including Patients With Idiopathic Myelofibrosis With Myeloid Dysplasia or Chronic Myelomonocytic Leukemia Completed NCT00136409 Phase 2 Imatinib mesylate
54 ALLOGENEIC MARROW OR PERIPHERAL BLOOD STEM CELL TRANSPLANTATION FOR AGNOGENIC MYELOID METAPLASIA WITH MYELOFIBROSIS Completed NCT00002792 Phase 2 busulfan;cyclophosphamide;cyclosporine;methotrexate;tacrolimus
55 Allogeneic Bone Marrow Transplantation for Patients With Chronic Myelogenous Leukemia in the Chronic Phase or Multiple Myeloma Completed NCT00004181 Phase 2 busulfan;cyclophosphamide
56 A Phase II Study of Lenalidomide (CC-5013) in Combination With Prednisone for the Treatment of Myelofibrosis With Myeloid Metaplasia Completed NCT00227591 Phase 2 lenalidomide;prednisone
57 Allogeneic Stem Cell Transplantation After Dose-reduced Intensity Conditioning Regimen for Patients With Myelofibrosis With Myeloid Metaplasia (MMM): A Phase II-study Completed NCT00599547 Phase 2
58 A Prospective Multicentre Phase II Trial of Zoledronic Acid in Patients With Myelofibrosis With Myeloid Metaplasia (MMM) Completed NCT00287261 Phase 2 zoledronic acid
59 A Phase 2, Prospective, Randomized, Multicenter, Double-blind, Active-control, Parallel-group Study to Determine the Safety of and to Select a Treatment Regimen of CC-4047 (Pomalidomide) Either as Single-agent or in Combination With Prednisone to Study Further in Subjects With Myelofibrosis With Myeloid Metaplasia Completed NCT00463385 Phase 2 Pomalidomide;Prednisone;Placebo to pomalidomide;Placebo to prednisone
60 A Phase 1/2 Study of Oral SB1518 in Subjects With Chronic Idiopathic Myelofibrosis Completed NCT00745550 Phase 1, Phase 2 SB1518
61 Ph I/II Study of PTK 787 (Vatalanib) and Gleevec (Imatinib) in Patients With Refractory Acute Myelogenous Leukemia (AML), Agnogenic Myeloid Metaplasia (AMM), and Chronic Myelogenous Leukemia- Blastic Phase (CML-BP) Completed NCT00088231 Phase 1, Phase 2 Imatinib Mesylate (Gleevec);PTK 787 (vatalanib)
62 Phase II Study of the Combination of Low-Dose Thalidomide, Prednisone, and Oral Cyclophosphamide ("TPC") in the Therapy of Myelofibrosis With Myeloid Metaplasia (MMM) Completed NCT00445900 Phase 2 cyclophosphamide;prednisone;thalidomide
63 A Phase II Trial of R115777 in Myelofibrosis With Myeloid Metaplasia (MMM) Completed NCT00047190 Phase 2 tipifarnib
64 A Phase 1/2 Study of SB1518 for the Treatment of Advanced Myeloid Malignancies Completed NCT00719836 Phase 1, Phase 2 SB1518
65 A Pilot Study of Thalidomide as an Inhibitor of Angiogenesis in the Treatment of Myelofibrosis With Myeloid Metaplasia (MMM) Completed NCT00015821 Phase 2 thalidomide
66 A Multi-Center, Open-Label, Phase II Study of Single-Agent GX15-070MS Administered as a 24-Hour Infusion Every 2 Weeks to Patients With Myelofibrosis With Myeloid Metaplasia (MF) Completed NCT00360035 Phase 2 Obatoclax mesylate (GX15-070MS)
67 Phase I/II Study of RAD001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Chronic Myeloid Leukemia in Blastic-Phase, Agnogenic Myeloid Metaplasia, Chronic Lymphocytic Leukemia, T-Cell Leukemia, or Mantle Cell Lymphoma Completed NCT00081874 Phase 1, Phase 2 RAD001
68 Therapy of Myeloid Metaplasia-Myelofibrosis, Atypical Chronic Myeloid or Myelomonocytic Leukemia, C-Kit Positive Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (AML-MDS), Hypereosinophilic Syndrome, Polycythemia Vera, and Mastocytosis With Dasatinib (BMS-354825) Completed NCT00255346 Phase 2 Dasatinib (BMS-354825)
69 A Phase II Trial of Combination Therapy With Thalidomide, Arsenic Trioxide, Dexamethasone, and Ascorbic Acid (TADA) in Patients With Chronic Idiopathic Myelofibrosis or Overlap Myelodysplastic/Myeloproliferative Disorders Completed NCT00274820 Phase 2 arsenic trioxide;dexamethasone;thalidomide
70 Autologous Peripheral Blood Stem Cell Mobilization and Transplantation for Myelofibrosis Completed NCT00006367 Phase 2 busulfan;cytarabine;idarubicin
71 Phase II Study of Perifosine in Patients With Refractory and Relapsed Leukemia Completed NCT00391560 Phase 2 perifosine
72 A Phase 2 Study to Evaluate the Efficacy and Safety of GS-6624 in Adult Subjects With Primary, Post Polycythemia Vera or Post Essential Thrombocythemia Myelofibrosis Completed NCT01369498 Phase 2 Simtuzumab;Ruxolitinib
73 Evaluation of CEP-701, an Orally Available JAK2 Tyrosine Kinase Inhibitor, as a Therapy for Patients With Myelofibrosis Completed NCT00494585 Phase 2 CEP-701
74 A Phase 2, Open-label, Translational Biology Study of Momelotinib in Transfusion-Dependent Subjects With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF) Completed NCT02515630 Phase 2 MMB
75 Open-label Study to Assess the Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post Essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia Completed NCT02124746 Phase 2 Momelotinib
76 Clinical and Pharmacodynamic Comparison of Continuous Versus Intermittent Dosing Regimens for Pomalidomide in Relapsed/Refractory Multiple Myeloma Completed NCT01319422 Phase 2 Pomalidomide
77 A Phase 2 Study of IPI-926 in Patients With Myelofibrosis Completed NCT01371617 Phase 2 IPI-926
78 A Multi-national Open-label Phase II Study of the JAK Inhibitor INC424 in Patients With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis Completed NCT01392443 Phase 2 Ruxolitinib
79 Conditioning With Targeted Busulfan, Cyclophosphamide and Thymoglobulin for Allogeneic Marrow or Peripheral Blood Stem Cell (PBSC) Transplantation for Myelodysplasia and Myeloproliferative Disorders Completed NCT00054340 Phase 1, Phase 2 busulfan;cyclophosphamide;cyclosporine;methotrexate
80 OUTPATIENT SUBCUTANEOUS IL-2 AND ALPHA INTERFERON IN THE MANAGEMENT OF METASTATIC CANCER Completed NCT00002504 Phase 2
81 Conditioning For Hematopoietic Cell Transplantation With Fludarabine Plus Targeted IV Busulfan and GVHD Prophylaxis With Thymoglobulin, Tacrolimus and Methotrexate in Patients With Myeloid Malignancies Completed NCT00346359 Phase 2 busulfan;fludarabine phosphate;methotrexate;tacrolimus
82 Phase II Trial of Oral Panobinostat (LBH589), a Novel Deacetylase Inhibitor (DACi) in Patients With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia (ET) Myelofibrosis and Post- Polycythemia Vera (PV) Myelofibrosis Completed NCT00931762 Phase 2 Panobinostat
83 Open-label, Phase II Clinical Trial of Aplidin® (Plitidepsin) in Patients With Primary Myelofibrosis (PMF) and Post Polycythemia Vera/Essential Thrombocythemia (Post-PV/ET) Myelofibrosis Completed NCT01149681 Phase 2 APLIDIN (plitidepsin)
84 HLA Matched Related and Unrelated Bone Marrow Transplantation With Busulfan/Cyclophosphamide and Post Transplantation Cyclophosphamide for Hematological Malignancies Completed NCT00134017 Phase 2 Busulfan;Cyclophosphamide
85 A Phase II Trial of Non-Myeloablative Conditioning and Transplantation of Partially HLA-Mismatched Bone Marrow for Patients With Hematologic Malignancies Completed NCT00134004 Phase 2 cyclophosphamide;fludarabine phosphate;mycophenolate mofetil;tacrolimus
86 Oral Beclomethasone Dipropionate Capsules for Treatment of Intestinal Graft-Versus-Host Disease: Compassionate Use in Patients With Contraindictions to High-Dose Immunosuppressive Therapy Completed NCT00010283 Phase 1, Phase 2 beclomethasone dipropionate
87 Purine-Analog-Containing Non-Myeloablative Allogeneic Stem Cell Transplantation for Treatment of Hematologic Malignancies and Severe Aplastic Anemia Completed NCT00006379 Phase 2 cyclophosphamide;fludarabine phosphate
88 Phase II Clinical Trial Incorporating Alemtuzumab (Campath-1H) in Combination With FK506 and Methylprednisolone for Treatment of Severe Acute Graft vs Host Disease Completed NCT00109993 Phase 2 methylprednisolone;tacrolimus
89 A Phase II Study of the Combination of Tacrolimus and Mycophenolate Mofetil for the Prevention of Acute Graft-Versus-Host Disease Completed NCT00096096 Phase 2 mycophenolate mofetil;tacrolimus
90 A Phase I/II Study of Sirolimus in Addition to Tacrolimus and Methotrexate for the Prevention of Acute-Graft-Versus-Host Disease in Patients Undergoing Hematopoietic Stem Cell Transplantation From Unrelated Donors Completed NCT00089037 Phase 1, Phase 2 methotrexate;sirolimus;tacrolimus
91 Treatment of Patients With Hematological Malignancies Using Marrow Transplantation From Unrelated Donors Incompatible for One HLA Locus Antigen Completed NCT00005804 Phase 2 cyclophosphamide
92 Donor Lymphocyte Infusion (DLI) as Adoptive Immunotherapy for Relapse Malignancies After Allogeneic Hematopoietic Transplantation Completed NCT00003887 Phase 2
93 Cytokine-Based Immunotherapy Following High-Dose Chemotherapy and Autologous Stem Cell Transplantation Completed NCT00003408 Phase 2
94 A Phase I-II Intensive-Dose Ifosfamide, Carboplatin and Taxotere (IC-T) Combination Chemotherapy Followed by Autologous Stem Cell Rescue for Patients With Refractory Malignancies Completed NCT00003406 Phase 1, Phase 2 carboplatin;docetaxel;ifosfamide
95 A PHASE II STUDY OF CELLULAR ADOPTIVE IMMUNOTHERAPY AS PROPHYLAXIS FOR CYTOMEGALOVIRUS DISEASE AFTER ALLOGENEIC BONE MARROW TRANSPLANTATION Completed NCT00002673 Phase 2
96 A Phase II Study to Evaluate Low-Dose Alemtuzumab as a Glucocorticoid-Sparing Agent for Initial Systemic Treatment of Acute Graft-Versus-Host Disease Completed NCT00410657 Phase 2 methylprednisolone;prednisone
97 A Phase II Study to Evaluate Efficacy and Tolerability of Methotrexate in Combination With Glucocorticoids for the Treatment of Newly Diagnosed Acute Graft-Versus-Host Disease After Nonmyeloablative Hematopoietic Cell Transplantation Completed NCT00357084 Phase 2 methotrexate;methylprednisolone;prednisone
98 Prospective, Phase II Randomized Study to Compare Busulfan-fludarabine Reduced-intensity Conditioning (RIC) With Thiotepa-fludarabine RIC Regimen Prior to Allogeneic Transplantation of Hematopoietic Cells for the Treatment of Myelofibrosis Completed NCT01814475 Phase 2 A: Fludarabine + Busulphan;B: Fludarabine + Thiotepa
99 A Phase 1/2, Open-Label Study of the JAK2 Inhibitor INCB018424 Administered Orally to Patients With Primary Myelofibrosis (PMF) and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis (Post-PV/ET) Completed NCT00509899 Phase 1, Phase 2 Ruxolitinib
100 An Open-label Assessment of Once-daily Dosing of a Sustained Release (SR) Formulation of INCB018424 in Patients With Primary Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, and Post-polycythemia Vera Myelofibrosis Completed NCT01340651 Phase 2 Ruxolitinib
101 An Open Label Assessment of Safety and Efficacy of Ruxolitinib (INCB018424) in Subjects With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia-myelofibrosis (PPV-MF) and Post Polycythemia Vera-myelofibrosis (PET-MF) Who Have Platelet Counts of 50 x 10^9/L to 100 x 10^9/L Completed NCT01348490 Phase 2 Ruxolitinib (INCB018424)
102 A Multicenter Phase II, Open Label, Single Arm Study to Evaluate the Efficacy and Safety of Ruxolitinib in the Treatment of Anemic Myelofibrosis Patients. Completed NCT02966353 Phase 2 ruxolitinib
103 Allogeneic Stem Cell Transplantation for Myelofibrosis and Myelodysplastic Syndrome Using Reduced Intensity Busulfan and Fludarabine Conditioning Completed NCT00475020 Phase 2 Busulfan;Fludarabine;Thymoglobulin (ATG)
104 Effects of Sympathicomimetic Agonists on the Disease Course and Mutant Allele Burden in Patients With JAK2-mutated Myeloproliferative Neoplasms. A Multicenter Phase II Trial. Completed NCT02311569 Phase 2 Mirabegron
105 A Phase II, Multicenter, Open Label, Single Arm Study of SAR302503 in Subjects Previously Treated With Ruxolitinib and With a Current Diagnosis of Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis Completed NCT01523171 Phase 2 SAR302503
106 An Open-Label Study to Evaluate the Long-Term Effects of Orally Administered SAR302503 in Patients With Primary or Secondary Myelofibrosis Completed NCT00724334 Phase 1, Phase 2 SAR302503 (TG101348)
107 Single Arm Salvage Therapy With Pegylated Interferon Alfa-2a for Patients With High Risk Polycythemia Vera or High Risk Essential Thrombocythemia Who Are Either Hydroxyurea Resistant or Intolerant or Have Had Abdominal Vein Thrombosis Completed NCT01259817 Phase 2 PEGASYS;Aspirin
108 A Phase 2 Pilot Trial of Ruxolitinib Combined With Danazol for Patients With Primary Myelofibrosis (MF), Post Essential Thrombocythemia-Myelofibrosis (Post ET) and Post Polycythemia Vera Myelofibrosis (PV MF) Suffering From Anemia Completed NCT01732445 Phase 2 ruxolitinib phosphate;danazol
109 Graft-versus-host Disease Prophylaxis With Post-transplantation Cyclophosphamide and Ruxolitinib in Patients With Myelofibrosis Completed NCT02806375 Phase 1, Phase 2 Busulfan;Fludarabine monophosphate;Cyclophosphamide;Ruxolitinib;Ruxolitinib
110 A Phase II, Open-Label Extension Study Evaluating the Long Term Safety, Tolerability & Efficacy of Orally-Administered CYT387 in Primary Myelofibrosis or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis Completed NCT01236638 Phase 2 Momelotinib
111 A Phase Ib/II, Open-label, Multi-center, Dose-finding Study to Assess the Safety and Efficacy of the Oral Combination of LDE225 and INC424 (Ruxolitinib) in Patients With Myelofibrosis Completed NCT01787552 Phase 1, Phase 2 LDE225;INC424
112 An Open-label Assessment of an Alternative Dosing Strategy of Ruxolitinib in Patients With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, and Post-essential Thrombocythemia Myelofibrosis Completed NCT01445769 Phase 2 Ruxolitinib
113 A Phase 2 Open-Label, Dose-Ranging Study of the Efficacy and Safety of Orally Administered SAR302503 in Japanese Patients With Intermediate-2 or High Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis With Splenomegaly Completed NCT01692366 Phase 2 SAR302503
114 A Phase II Study Of Gleevec (Imatinib Mesylate Formerly Known as STI-571) In Patients With Myelofibrosis Completed NCT00039416 Phase 2 imatinib mesylate
115 Panobinostat and Ruxolitinib In MyElofibrosis (PRIME STUDY) - Phase I/II Study of Combination Oral JAK2 Tyrosine Kinase Inhibitor (JAK2-TKI) and Histone Deacetylase Inhibitor (HDACI) Therapy in Patients With Myelofibrosis Completed NCT01693601 Phase 1, Phase 2 Panobinostat;Ruxolitinib
116 A Pilot Open-Label Study of the Efficacy and Safety of Imetelstat (GRN163L) in Myelofibrosis and Other Myeloid Malignancies Completed NCT01731951 Phase 2 Imetelstat
117 A Phase I/II, Open-Label Study Evaluating Twice-Daily Administration of CYT387 in Primary Myelofibrosis or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis Completed NCT01423058 Phase 1, Phase 2 Momelotinib
118 Phase II Study of Azacitidine in Myelofibrosis Completed NCT00569660 Phase 2 Azacitidine
119 A Phase 2 Randomized, Open-Label, Dose-Ranging Study of the Efficacy and Safety of Orally Administered SAR302503 in Patients With Intermediate-2 or High Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis With Splenomegaly Completed NCT01420770 Phase 2 SAR302503
120 A Phase I/II, Open-Label, Dose-Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally-Administered CYT387 in Primary Myelofibrosis or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis. Completed NCT00935987 Phase 1, Phase 2 CYT387
121 A Phase II Study of Reduced-Intensity Allogeneic Peripheral Blood Stem Cell Transplantation (PBSCT) for Treatment of Hematologic Malignancies and Hematopoietic Failure States Completed NCT00997386 Phase 2 busulfan, and melphalan, and alemtuzumab
122 A Phase II Study of AP23573, an mTOR Inhibitor, in Patients With Relapsed or Refractory Hematologic Malignancies Completed NCT00086125 Phase 2 ridaforolimus
123 Study of Fludarabine Based Conditioning for Allogeneic Stem Cell Transplantation for Myelofibrosis Completed NCT00572897 Phase 2 Fludarabine, Melphalan +/- ATG
124 Prevention of DMSO-Related Nausea and Vomiting by Prophylactic Administration of Ondansetron for Patients Receiving Autologous Cryopreserved Peripheral Blood Stem Cells Completed NCT00795769 Phase 2 ondansetron
125 Impact of Intervention With Deferasirox on the Immune Function of Patients With Hematologic Diseases and Transfusion-Related Iron Overload Completed NCT01273766 Phase 2 deferasirox
126 Evaluation of Lenalidomide (CC-5013) and Prednisone as a Therapy for Patients With Myelofibrosis (MF) Completed NCT00352794 Phase 2 Lenalidomide;Prednisone
127 Phase II Study of CC-5013 in Myelofibrosis Completed NCT00087672 Phase 2 CC-5013
128 A Phase II Study to Evaluate the Efficacy of Oral Beclomethasone Dipropionate for Prevention of Acute GVHD After Hematopoietic Cell Transplantation With Myeloablative Conditioning Regimens Completed NCT00489203 Phase 2 beclomethasone dipropionate;placebo;tacrolimus;methotrexate
129 A Phase I/II Combination Study of Topotecan, Fludarabine, Cytosine Arabinoside and G-CSF (T-FLAG) Induction Therapy in Patients With Poor Prognosis AML, MDS and Relapsed/Refractory ALL Followed by Maintenance of Either PBSC Transplant or 13 Cis-Retinoic Acid Completed NCT00003619 Phase 1, Phase 2 busulfan;cytarabine;etoposide;fludarabine phosphate;isotretinoin;topotecan hydrochloride
130 Phase II Trial of Triapine (NSC #663249, 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbone) Plus Fludarabine (NSC #312887, Fludarabine Monophosphate) in Adults With Aggressive Myeloproliferative Disorders (MPDs) Including Chronic Myelomonocytic Leukemia (CMML) and Chronic Myelogenous Leukemia in Accelerated Phase (CML-AP) or Blast Crisis (CML-BC) Completed NCT00381550 Phase 2 fludarabine phosphate;triapine
131 Transplantation of Unrelated Umbilical Cord Blood for Patients With Hematological Diseases With Cyclophosphamide/Fludarabine/Total Body Irradiation Myeloablative Preparative Regimen Completed NCT00309842 Phase 2 cyclophosphamide;cyclosporine;fludarabine phosphate;mycophenolate mofetil
132 Evaluation of Ruxolitinib and Lenalidomide Combination as a Therapy for Patients With Myelofibrosis Completed NCT01375140 Phase 2 Ruxolitinib;Lenalidomide;Prednisone
133 Evaluation of Ruxolitinib and Pracinostat Combination as a Therapy for Patients With Myelofibrosis Completed NCT02267278 Phase 2 Ruxolitinib;Pracinostat
134 A Phase 2, Prospective, Open-Label Study to Determine the Safety and Efficacy of SB939, A Histone Deacetylase Inhibitor, in Subjects With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis (PMF; Post-Polycythemia Vera (PV) Myelofibrosis (MF), Or Post- Essential Thrombosis (ET) MF Completed NCT01200498 Phase 2 SB939
135 A Pilot Study of EPOCH-F/R Induction Chemotherapy and Reduced-Intensity, HLA-Matched, Related Allogeneic Hematopoietic Stem Cell Transplantation, With Cyclosporine & Methotrexate GVHD Prophylaxis for Refractory or Relapsed Hematologic Malignancies Completed NCT00051311 Phase 2
136 A Two-part Study Top Assess the Safety and Preliminary Efficacy of Givinostat in Patients With JAK2V617F Positive Polycythemia Vera Completed NCT01901432 Phase 1, Phase 2 Givinostat
137 A Phase II Single-Arm Study of the Efficacy and Safety of Oral Rigosertib in Patients With Myelofibrosis (MF) and Anemia Completed NCT02730884 Phase 2 Rigosertib
138 A Phase II Trial of Reduced Intensity Allogeneic Stem Cell Transplantation With Fludarabine, Melphalan and Low Dose Total Body Irradiation Completed NCT01529827 Phase 2 fludarabine phosphate;melphalan;tacrolimus;mycophenolate mofetil;methotrexate
139 Allogeneic Bone Marrow Transplantation Using Closely Matched Related and Unrelated Donors Completed NCT00005622 Phase 2 cyclophosphamide
140 A Phase 2, Open Label Efficacy and Safety Study of Anagrelide Controlled Release (CR) in Subjects With Thrombocytosis Secondary to Essential Thrombocythemia and Other Myeloproliferative Neoplasms (MPN) Completed NCT02125318 Phase 2 Anagrelide CR
141 A Phase II Study of Sirolimus, Tacrolimus and Thymoglobulin, as Graft-versus-Host Prophylaxis in Patients Undergoing Unrelated Donor Hematopoietic Cell Transplantation Completed NCT00589563 Phase 2 cyclophosphamide;etoposide;fludarabine phosphate;melphalan;methotrexate;sirolimus;tacrolimus
142 A Phase II, Prospective, Open Label Study (PO-MMM-PI-0011) to Determine the Safety and Efficacy of Pomalidomide (CC-4047) in Subjects With Primary, Post Polycythemia Vera, or Post Essential Thrombocythemia Myelofibrosis (PMF; Post-PV MF, or Post-ET MF) Completed NCT00946270 Phase 2 CC-4047;Prednisone;CC-4047
143 Matched Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplantation With a Conditioning Regimen of Targeted Busulfan, Cyclophosphamide, and Thymoglobulin Completed NCT00611351 Phase 2 busulfan;cyclophosphamide;mycophenolate mofetil;tacrolimus
144 Donor NK Cell Infusion for Progression/Recurrence of Underlying Malignant Disorders After HLA-haploidentical HCT - a Phase 1-2 Study Completed NCT00823524 Phase 1, Phase 2
145 Phase II Study of Allogeneic Transplant of Hematopoietic Stem Cells From a Compatible Family Donor in the Treatment of Patients Over 55 Years With Hematological Malignancies Completed NCT00806767 Phase 2 busulfan;fludarabine phosphate
146 A Phase I-II Safety, Tolerability And Pharmacokinetic Study Of Ravuconazole For Prophylaxis Of Invasive Fungal Infections In Patients Undergoing Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation Completed NCT00064311 Phase 1, Phase 2 ravuconazole
147 Non-Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies and Aplastic Anemia Completed NCT00053989 Phase 2 cyclophosphamide;fludarabine phosphate;methylprednisolone;mycophenolate mofetil;tacrolimus
148 Allogeneic Bone Marrow Transplantation for Hematologic Malignancies: A Treatment Approach Based on Risk of Relapse and Toxicity Completed NCT00005797 Phase 2 busulfan;Cyclophosphamide;VP-16
149 Allogeneic Hematopoietic Cell Transplantation for Patients With Hematologic Disorders Who Are Undergoing Dose-Adjusted Treatment With A Maximally Intensive Busulfex-Based Therapeutic Regimen Completed NCT00448357 Phase 1, Phase 2 busulfan;fludarabine phosphate;tacrolimus;methotrexate
150 A Multicenter, Open, Phase II Study to Estimate the Activity and Safety of Caspofungin (CASP) in the First-Line Treatment of Probable and Proven Invasive Aspergillosis (IA) in Patients With Hematological Malignancies (HM) or Recipients of Autologous Haematopoietic Stem Cell Transplantation and Those With Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) Completed NCT00110045 Phase 2 caspofungin acetate
151 A Phase II Study of Sirolimus, Tacrolimus and Thymoglobulin®, as Graft-versus-Host- Disease Prophylaxis in Patients Undergoing Unrelated Donor Hematopoietic Cell Transplantation Completed NCT00691015 Phase 2 busulfan;carmustine;cyclophosphamide;cytarabine;etoposide;fludarabine phosphate;melphalan;anti-thymocyte globulin IV
152 Multi-Center Phase II Study With Pomalidomide in Patients With Myeloproliferative Neoplasms in Fibrotic Stage Completed NCT00949364 Phase 2 Pomalidomide
153 Allogeneic Hematopoietic Cell Transplantation for Patients With Hematologic Disorders Who Are Ineligible or Inappropriate for Treatment With a More Intensive Therapeutic Regimen Completed NCT00448201 Phase 2 busulfan;fludarabine phosphate;methotrexate;tacrolimus
154 Pre-administration of Rabbit Antithymocyte Globulin to Optimize Donor T-Cell Engraftment Following Reduced Intensity Allogeneic Peripheral Blood Progenitor Cell Transplantation From Matched-Related Donors Completed NCT00787761 Phase 2 busulfan;cyclophosphamide;fludarabine phosphate;methotrexate;tacrolimus
155 A Phase I/II Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplant for the Treatment of Patients With Hematologic Malignancies Using Busulfan, Fludarabine and Total Body Irradiation Completed NCT00245037 Phase 1, Phase 2 busulfan;cyclosporine;fludarabine phosphate;mycophenolate mofetil;Granulocyte colony-stimulating factor (G-CSF);Phenytoin;Methotrexate
156 A Phase IIA Study of the Histone-deacetylase Inhibitor ITF2357 in Patients With JAK-2 V617F Positive Chronic Myeloproliferative Diseases Completed NCT00606307 Phase 2 ITF2357
157 Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases Completed NCT00154388 Phase 2 Imatinib mesylate
158 Traditional Chinese Medicine in the Supportive Management of Anaemic and Cytopenic (Leukopenia, Thrombocytopenia) Haematological Disorders Completed NCT01224496 Phase 1, Phase 2 Chinese herbal concoction twice a day for 6 months
159 A Randomized, Pilot Study of Ruxolitinib in Antiretroviral-Treated HIV-Infected Adults Completed NCT02475655 Phase 2 Ruxolitinib
160 Multicenter Phase 2 Study of Efficacy and Safety of Pegylated Interferon-alfa 2a in Polycythemia Vera Patients Completed NCT00241241 Phase 2 pegylated interferon-alfa 2a
161 A Phase II Trial of Post-Transplant Cyclophosphamide and Sirolimus for Graft-versus-host Disease (GVHD) Prophylaxis Following Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation Completed NCT01244906 Phase 2
162 T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies Completed NCT00683046 Phase 2 Fludarabine;Melphalan;Stem cells;Campath
163 A Phase II Study of Tacrolimus and Thymoglobulin, as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Related Donor Hematopoietic Cell Transplantation Completed NCT01246206 Phase 2 Tacrolimus and Thymoglobulin
164 An Open-Label Pilot Study to Evaluate the Efficacy of Ruxolitinib in Moderate to Severe Alopecia Areata Completed NCT01950780 Phase 2 Ruxolitinib
165 Evaluation of the Incidence and Prognostic Impact of Molecular and Genetic Abnormalities in Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome and Myeloproliferative Neoplasms Completed NCT02084563 Phase 2 Induction Chemotherapy;Consolidation Chemotherapy;Autologous Stem Cell Transplantation;Allogeneic Stem Cell Transplantation;Low Dose Cytarabine;Decitabine
166 A Randomized Phase 2 Single-Center Study of Pomalidomide for Chronic GvHD Completed NCT01688466 Phase 2 Pomalidomide
167 Multicenter Phase I/II Trial of Ruxolitinib in Combination With Decitabine in Patients With Accelerated Phase Myeloproliferative Neoplasm (MPN) or Post-MPN AML Completed NCT02076191 Phase 1, Phase 2 Ruxolitinib;Decitabine
168 An Open-label Phase II Study of Lorvotuzumab Mertansine (IMGN901) in CD56 Expressing Hematological Malignancies Completed NCT02420873 Phase 2 Lorvotuzumab Mertansine (IMGN901)
169 Phase II Study of Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome Completed NCT00882102 Phase 2 Decitabine;Gemtuzumab ozogamicin
170 Phase II Study of INCB018424 in Patients With Advanced Hematologic Malignancies Completed NCT00674479 Phase 2 INCB018424
171 A Phase 1/2, Single Arm Study To Assess the Efficacy and Safety of Rigosertib (ON 01910.Na) Administered as 72-Hour and 120-Hour Continuous Intravenous Infusions Every Other Week for Two Cycles Then as Twice Daily Oral Capsules Given Continuously in Patients With Relapsed/Refractory Acute Myeloid or Lymphocytic Leukemia or Transformed Myeloproliferative Neoplasms Completed NCT01167166 Phase 1, Phase 2 rigosertib
172 A Phase 2 Open-Label Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Subjects With Myelofibrosis Recruiting NCT03222609 Phase 2 Ruxolitinib;Navitoclax
173 Ruxolitinib Versus Allogeneic Stem Cell Transplantation for Patients With Myelofibrosis According to Donor Availability: A Prospective Phase II Trial (MMM 02 Study) Recruiting NCT03333187 Phase 2 Ruxolitinib continuous therapy
174 A Phase II Study to Evaluate the Efficacy and Safety of Selinexor in Patients With Myelofibrosis Refractory or Intolerant to JAK1/2 Inhibitors Recruiting NCT03627403 Phase 2 Selinexor
175 A Randomized, Open-label, Phase I/II Open Platform Study Evaluating Safety and Efficacy of Novel Ruxolitinib Combinations in Myelofibrosis Patients Recruiting NCT04097821 Phase 1, Phase 2 Ruxolitinib;Siremadlin;Crizanlizumab;MBG453
176 An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis Recruiting NCT03144687 Phase 2 Itacitinib;Ruxolitinib
177 A Multi-Center, Open Label Study to Assess the Safety, Steady-State Pharmacokinetics and Pharmacodynamics of IMG-7289 in Patients With Myelofibrosis Recruiting NCT03136185 Phase 2 IMG-7289
178 An Open-Label, Phase 2a/2b Study of KRT-232 in Subjects With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post-ET-MF) Who Have Failed a JAK Inhibitor Recruiting NCT03662126 Phase 2 KRT-232
179 Open Label Phase 2 Single Agent Study of LCL-161 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF) Recruiting NCT02098161 Phase 2 Smac Mimetic LCL161
180 A Phase 2,Multi-center, Open-label Study Evaluating Safety and Efficacy of Jaktinib Dihydrochloride Monohydrate in Intermediate-risk and High-risk Myelofibrosis. Recruiting NCT03886415 Phase 2 Jaktinib hydrochloride tablets
181 A Phase 1/2 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins: Phase 1 (in Patients With Hematological Malignancies) and Phase 2 (Dose Expansion of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis) Recruiting NCT02158858 Phase 1, Phase 2 CPI-0610;Ruxolitinib
182 A Phase-2 Study To Determine Efficacy and Safety of Luspatercept in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis and Anemia With or Without Red Blood Cell-Transfusion Dependence Recruiting NCT03194542 Phase 2 Luspatercept
183 Phase II Study of P1101 in Early Myelofibrosis Recruiting NCT02370329 Phase 2
184 A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis Recruiting NCT02718300 Phase 2 Parsaclisib;Parsaclisib;Ruxolitinib;Parsaclisib;Parsaclisib
185 Evaluation of Ruxolitinib And Thalidomide Combination as a Therapy for Patients With Myelofibrosis Recruiting NCT03069326 Phase 2 Ruxolitinib;Thalidomide
186 Evaluation of Ruxolitinib and Azacytidine Combination as a Therapy for Patients With Myelofibrosis and Myelodysplastic Syndrome/ Myeloproliferative Neoplasm Recruiting NCT01787487 Phase 2 Azacitidine;Ruxolitinib Phosphate
187 SL-401 in Patients With Advanced, High Risk Myeloproliferative Neoplasms (Systemic Mastocytosis, Advanced Symptomatic Primary Eosinophilic Disorder, Myelofibrosis, Chronic Myelomonocytic Leukemia) Recruiting NCT02268253 Phase 1, Phase 2 SL-401
188 A Phase-2, Prospective, Open-Label Study to Determine the Safety and Efficacy of Sotatercept (ACE-011) in Subjects With Myeloproliferative Neoplasm (MPN) -Associated Myelofibrosis and Anemia Recruiting NCT01712308 Phase 2
189 A Phase-Ib/II Study of Ruxolitinib and Pomalidomide Combination Therapy in Patients With Primary and Secondary Myelofibrosis Recruiting NCT01644110 Phase 1, Phase 2 INCB018424/CC-4047
190 Phase 1/2 Randomized Trial Combination of Ruxolitinib and Peg-interferon Alpha-2a in Patients With Primary Myelofibrosis Post-polycythemia Vera-myelofibrosis or Post-essential Thrombocythemia-myelofibrosis Recruiting NCT02742324 Phase 1, Phase 2 Ruxolotinib;peg-IFN alpha -2a
191 Allogeneic Stem Cell Transplantation for Multiple Myeloma and Myelofibrosis Recruiting NCT03303950 Phase 2 Busulfan;Cyclophosphamide;Fludarabine
192 JAK Inhibitor Prior to Allogeneic Stem Cell Transplant for Patients With Primary and Secondary Myelofibrosis: A Prospective Study Recruiting NCT02251821 Phase 2 Busulfan;Cyclophosphamide;Fludarabine Phosphate;Melphalan;Methotrexate;Mycophenolate Mofetil;Ruxolitinib;Tacrolimus
193 A Phase II Trial in Patients With Myelofibrosis (Primary, Post-ET or Post PV-MF) Treated With the Selective JAK2 Inhibitor Pacritinib Before Reduced-intensity Conditioning Allogeneic Stem Cell Transplantation Recruiting NCT03645824 Phase 2 Pacritinib
194 Ruxolitinib Versus Best Available Therapy in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia - The Ruxo-BEAT Trial Recruiting NCT02577926 Phase 2 Ruxolitinib;BAT
195 A Phase II Study of Ruxolitinib Pre-, During- and Post-Hematopoietic Stem Cell Transplantation for Patients With Primary or Secondary Myelofibrosis. Recruiting NCT03427866 Phase 2 Ruxolitinib
196 PD-1 Inhibition in Advanced Myeloproliferative Neoplasms Recruiting NCT03065400 Phase 2 Pembrolizumab
197 A Phase I/II Study of Azacitidine, Venetoclax and Pevonedistat in Adults With Newly Diagnosed Secondary or Therapy-Related AML Recruiting NCT03862157 Phase 1, Phase 2 Azacitidine;Pevonedistat;Venetoclax
198 A Two Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies Recruiting NCT01384513 Phase 2 Fludarabine;Busulfan;Cyclophosphamide (CY);Tacrolimus;Mycophenolate mofetil
199 A Two Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Hematologic Malignancies Recruiting NCT01760655 Phase 2 Fludarabine phosphate;Thiotepa;Cyclophosphamide;Tacrolimus;Mycophenolate mofetil
200 Phase I/II Study De-Intensifying Exposure of Post-Transplantation Cyclophosphamide as GVHD Prophylaxis After HLA-Haploidentical Hematopoietic Cell Transplantation for Hematologic Malignancies Recruiting NCT03983850 Phase 1, Phase 2 Busulfan;Fludarabine;Cyclophosphamide;Mycophenolate Mofetil;Sirolimus
201 A Phase 1/2, Open-Label, Dose-Escalation/Dose-Expansion, Safety and Tolerability Study of INCB059872 in Subjects With Advanced Malignancies Recruiting NCT02712905 Phase 1, Phase 2 INCB059872;all-trans retinoic acid (ATRA);azacitidine;nivolumab
202 Desferal Administration to Improve the Impaired Reaction to Hypoxia in Diabetes Recruiting NCT03085771 Phase 2 desferal;Isotonic saline
203 Phase II Study Testing Prophylaxis Feasibility of Graft Versus Host Disease With Only High Dose Cyclophosphamide Post-transplantation for Patients Eligible to a Reduced-intensity Conditioning Regiment Prior to Allogenic Transplantation With a Compatible Familial or Non-familial Donor. Recruiting NCT03263767 Phase 2 Fludarabine;Clofarabine;Cyclophosphamide;Cyclophosphamide
204 A Phase 1/2 Study of INCB053914 in Subjects With Advanced Malignancies Recruiting NCT02587598 Phase 1, Phase 2 INCB053914;INCB053914;I-DAC (Intermediate dose cytarabine);Azacitidine;Ruxolitinib
205 Reduced Intensity (RIC) Conditioning And Transplantation of HLA-Haploidentical Related Hematopoietic Cells (Haplo-HCT) For Patients With Hematologic Malignancies Recruiting NCT02988466 Phase 2 GVHD Prophylaxis
206 A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression Recruiting NCT02891603 Phase 1, Phase 2 Pacritinib;Sirolimus;Tacrolimus
207 Efficacy of Tyrosine Kinase Inhibition in Reducing Eosinophilia in Patients With Myeloid and/or Steroid-Refractory Hypereosinophilic Syndrome Recruiting NCT00044304 Phase 2 Imatinib;Ruxolitinib
208 Timed Sequential Busulfan and Post Transplant Cyclophosphamide for Allogeneic Transplantation Recruiting NCT02861417 Phase 2 Busulfan;Cyclophosphamide;Fludarabine;Fludarabine Phosphate;Mycophenolate Mofetil;Tacrolimus;Thiotepa
209 A Phase II Study of SGI-110 in Philadelphia-Negative Myeloproliferative Neoplasms Recruiting NCT03075826 Phase 2 SGI-110
210 A Phase II Study of Decitabine in Myelofibrosis Active, not recruiting NCT00095784 Phase 2 Decitabine
211 An Open-Label, Multiple Simon 2-Stage Study of Itacitinib Administered Orally to Subjects With Primary Myelofibrosis (PMF), Post Polycythemia Vera Myelofibrosis (PPV-MF) or Post Essential Thrombocythemia Myelofibrosis (PET-MF) Active, not recruiting NCT01633372 Phase 2 itacitinib
212 A Phase 1/2, Open-label, Dose-Escalation Multi-center Study to Assess the Safety, Tolerability, PK and PD of Orally Administered NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF Active, not recruiting NCT01423851 Phase 1, Phase 2 NS-018
213 A Phase II Trial of Allogeneic Peripheral Blood Stem Cell Transplantation From Matched Unrelated Donors in Patients With Advanced Hematologic Malignancies and Hematological Disorders Active, not recruiting NCT00544115 Phase 2 busulfan;cyclophosphamide;cyclosporine;etoposide;fludarabine phosphate;melphalan;methotrexate;mycophenolate mofetil;sirolimus;tacrolimus
214 JAK2 Inhibitors RUXOLITINIB in Patients With High or Intermediate Risk Primary or Secondary Myelofibrosis Eligible for Allogeneic Stem Cell Transplantation: a Prospective Multicentric Phase II Study Active, not recruiting NCT01795677 Phase 2 Ruxolotinib
215 Open-Label Roll-Over Study to Assess the Long-Term Safety and Efficacy of Ruxolitinib in Subjects With Myelofibrosis Active, not recruiting NCT02784496 Phase 2 Ruxolitinib
216 An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis Previously Treated With Ruxolitinib Active, not recruiting NCT03165734 Phase 2 Pacritinib
217 A Phase 2, Prospective Study Of PRM-151 In Subjects With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV MF), Or Post-Essential Thrombocythemia MF (Post-ET MF) Active, not recruiting NCT01981850 Phase 2
218 A Phase I/II, Prospective, Open-Label Study to Determine the Safety and Efficacy of CC-4047 in Patients With Primary, Post Polycythemia Vera, or Post Essential Thrombocythemia Myelofibrosis® Active, not recruiting NCT00669578 Phase 1, Phase 2 CC-4047
219 Phase II Clinical Trial of the Use of Post-Transplant Cyclophosphamide for Graft Versus Host Disease (GvHD) Prophylaxis Following Matched Unrelated Donor (MUD) and Mismatched Unrelated Donor (MMUD)Hematopoietic Stem Cell Transplant (HSCT) Active, not recruiting NCT02065154 Phase 2 Cyclophosphamide
220 A Randomized, Single-Blind, Multicenter Phase 2 Study to Evaluate the Activity of 2 Dose Levels of Imetelstat in Subjects With Intermediate-2 or High-Risk Myelofibrosis (MF) Relapsed/Refractory to Janus Kinase (JAK) Inhibitor Active, not recruiting NCT02426086 Phase 2 Imetelstat 9.4 milligram/kilogram (mg/kg);Imetelstat 4.7 mg/kg
221 Long-term Study Evaluating the Effect of Givinostat in Patients With JAK2V617F Positive Chronic Myeloproliferative Neoplasms Active, not recruiting NCT01761968 Phase 2 Givinostat
222 A Multi-Center Study of Nonmyeloablative Conditioning With TBI or Fludarabine/TBI for HLA-matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies With Post Grafting Immunosuppression With Tacrolimus and Mycophenolate Mofetil Active, not recruiting NCT00089011 Phase 2 fludarabine phosphate;mycophenolate mofetil;tacrolimus
223 Low-Dose TBI Dose Escalation to Decrease Risks of Progression and Graft Rejection After Hematopoietic Cell Transplantation With Nonmyeloablative Conditioning as Treatment for Untreated Myelodysplastic Syndrome or Myeloproliferative Disorders - A Multi-Center Trial Active, not recruiting NCT00397813 Phase 2 Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil
224 A Phase 2 Study of LY2784544 in Patients With Myeloproliferative Neoplasms Active, not recruiting NCT01594723 Phase 2 120 mg LY2784544
225 A Pilot Study of a Thrombopoietin-Receptor Agonist (TPO-R Agonist), Eltrombopag, in Patients With Low to Int-2 Risk Myelodysplastic Syndrome (MDS) Active, not recruiting NCT00961064 Phase 2 Eltrombopag
226 Phase I/II Trial of Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer Active, not recruiting NCT02066532 Phase 1, Phase 2 Ruxolitinib;Trastuzumab
227 A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML) and Cataloging the Molecular Consequences of JAK2 Inhibition in Chronic Myelomonocytic Leukemia: A Correlative Study Identifying Targetable CMML Sub-Clones by Leveraging GM-CSF Dependent pSTAT Hypersensitivity Active, not recruiting NCT01776723 Phase 1, Phase 2 Ruxolitinib
228 Extended Access of Momelotinib for Subjects With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF) Enrolling by invitation NCT03441113 Phase 2 MMB
229 A Phase 2 Study of WEE1 Inhibition and AZD1775 Alone or Combined With Cytarabine in Patients With Advanced Acute Myeloid Leukemia, Myelodysplastic Syndrome and Myelofibrosis Not yet recruiting NCT03718143 Phase 2 Combination AZD1775 with AraC;AZD1775 only
230 Itacitinib to Prevent Graft Versus Host Disease Not yet recruiting NCT04127721 Phase 2 Busulfan;Fludarabine;Itacitinib;Methotrexate;Tacrolimus
231 A Randomized Phase II Study to Compare ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation Not yet recruiting NCT03602898 Phase 2 Busulfan;Cyclophosphamide;Cyclosporine;Fludarabine Phosphate;Methotrexate;Tacrolimus
232 Study of the Anti-EphA3 Monoclonal Antibody KB004 in Subjects With EphA3-Expressing Hematologic Malignancies Suspended NCT01211691 Phase 1, Phase 2 KB004, Monoclonal Antibody
233 A Phase II Pilot Study to Determine the Safety and Preliminary Efficacy of Imatinib Mesylate (Gleevec) in Patients With Myelofibrosis With Myeloid Metaplasia Terminated NCT00245128 Phase 2 imatinib mesylate
234 A Phase I/IIa Open-label Study to Assess the Safety, Tolerability and Preliminary Efficacy of AT9283, a Small Molecule Inhibitor of Aurora Kinases, in Patients With Refractory Hematological Malignancies Terminated NCT00522990 Phase 1, Phase 2 AT9283
235 Phase 2 Study of Nivolumab in Patients With Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, or Post-Polycythemia Vera Myelofibrosis Terminated NCT02421354 Phase 2
236 A Phase II Study of Sunitinib Malate in Idiopathic Myelofibrosis Terminated NCT00387426 Phase 2 sunitinib malate
237 Phase II Study of Azacitidine in Myelofibrosis Terminated NCT00381693 Phase 2 azacitidine
238 Phase II Study of Bevacizumab (Avastin®) in Myelofibrosis Terminated NCT00667277 Phase 2 bevacizumab (Avastin)
239 Pilot Study Of T-Cell-Depleted Peripheral Blood Stem Cell Transplantation From Partially Matched Related Donors For Patients With High-Risk Leukemia Terminated NCT00066417 Phase 2 cyclophosphamide;cyclosporine;fludarabine phosphate;methylprednisolone;therapeutic allogeneic lymphocytes;thiotepa
240 Transplantation of Two Partially Matched Umbilical Cord Blood Units Following Reduced Intensity Conditioning to Enhance Engraftment and Limit Transplant-Related Mortality in Adults With Hematologic Malignancies Terminated NCT00827099 Phase 2 fludarabine phosphate;Melphalan;mycophenolate mofetil;tacrolimus
241 Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematological Malignancies Using a Non-Myeloablative Preparative Regimen Terminated NCT00719849 Phase 2 cyclophosphamide;cyclosporine;fludarabine phosphate;mycophenolate mofetil
242 Phase II Trial of Low Dose Decitabine (Dacogen) in Patients With Primary Myelofibrosis and Post ET/PV Myelofibrosis Terminated NCT00630994 Phase 2 Dacogen
243 A Phase 2, Double-blind, Randomized Safety And Efficacy Study Of Glasdegib (Pf-04449913) Versus Placebo In Patients With Myelofibrosis Previously Treated With Ruxolitinib Terminated NCT02226172 Phase 2 Glasdegib (PF-04449913);Placebo
244 Phase II Randomized Controlled Trial of Pegylated Interferon Alpha-2b in Early Primary Myelofibrosis Terminated NCT01758588 Phase 2 Peginterferon alfa-2a
245 A Phase II Study of the HSP90 Inhibitor, AUY922, in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), and Refractory PV/ET Terminated NCT01668173 Phase 2 AUY922
246 The ReTreatment Trial: A Phase II, Open-label, Single-arm Study of Re-treating Myelofibrosis Patients With Ruxolitinib/Jakavi After Treatment Interruption Due to Loss of Response and/or Adverse Event. Terminated NCT02091752 Phase 2 Ruxolitinib
247 Exploring the Potential of Dual Kinase JAK 1/2 Inhibitor Ruxolitinib (INC424) With Reduced Intensity Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis Terminated NCT01790295 Phase 2 Ruxolitinib Pre- Hematopoietic cell transplantation (HCT)
248 A Phase 1/2, Open-Label, Uncontrolled, Multiple Dose Escalation, Cohort Expansion Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Preliminary Efficacy Of Asn002 In Relapsed/Refractory Lymphoma, Myelofibrosis, Chronic Lymphocytic Leukemia, And Advanced Solid Tumors Terminated NCT02440685 Phase 1, Phase 2 ASN002 Dose Escalation;ASN002 RD
249 Management of Venous Thromboembolic Events (VTE) in Patients With Hematologic Disorders and Treatment-Induced Thrombocytopenia: A Pilot Study Terminated NCT03195010 Phase 2
250 Deferasirox Treatment and Labile Plasma Iron in Iron Overloaded Patients Who Have Undergone Allogeneic Hematopoietic Stem Cell Transplantation Terminated NCT01159067 Phase 2 deferasirox
251 A Phase I/II Study to Determine the Safety and Efficacy of Ruxolitinib, a JAK1/JAK2 Inhibitor, in Subjects With Relapsed or Refractory Acute Leukemia Terminated NCT01251965 Phase 1, Phase 2 Ruxolitinib
252 Allogeneic Bone Marrow Transplantation for Marrow Failure States Terminated NCT00005852 Phase 2 cyclophosphamide;cyclosporine;methylprednisolone
253 Safety And Efficacy of Sub-Myeloablative Allogeneic Stem Cell Transplantation For Patients With Myeloproliferative Disorder (MPD), Myelodysplastic Syndrome (MDS), Acute Myelogenous Leukemia (AML) or Chronic Myelogenous Leukemia Terminated NCT00069992 Phase 2 Fludarabine;Campath 1H
254 T-Cell Depletion for Graft-Versus-Host Disease (GVHD) Prevention in High Risk Matched and Mismatched Allogeneic Bone Marrow Transplantation Terminated NCT00005641 Phase 2 busulfan;cyclophosphamide;cyclosporine;leucovorin calcium;methotrexate;methylprednisolone
255 Conditioning for Graft Failure After Hematopoietic Stem Cell Transplantation Terminated NCT00617929 Phase 2 clofarabine
256 A Phase 1/2 Multiple Ascending Dose Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of BMS-911543 in Subjects With Myelofibrosis Terminated NCT01236352 Phase 1, Phase 2 BMS-911543
257 A Pilot Phase II Study of Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation Terminated NCT01116232 Phase 2 sirolimus;tacrolimus
258 Transplantation of Unrelated Donor Hematopoietic Stem Cells for the Treatment of Hematological Malignancies Terminated NCT00281879 Phase 2 busulfan;carmustine;cyclophosphamide;cyclosporine;cytarabine;etoposide;fludarabine phosphate;melphalan;methotrexate;methylprednisolone;mycophenolate mofetil;tacrolimus
259 Multicentre Phase 2 Trial to Evaluate the Efficacy of Ruxolitinib in Steroid-refractory Acute Multicenter, Randomized Phase 2 Trial to Determine the Response Rate of Ruxolitinib and Best Available Treatment (BAT) Versus BAT in Steroid-refractory Acute Graft-versus-Host Disease (aGvHD) Terminated NCT02396628 Phase 2 Experimental intervention;Standard treatment
260 A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054329 in Subjects With Advanced Malignancies Terminated NCT02431260 Phase 1, Phase 2 INCB054329 Monotherapy
261 A Phase 1/2, Open-Label, Dose-Escalation/Dose-Expansion, Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies Terminated NCT02711137 Phase 1, Phase 2 INCB057643;INCB057643;Gemcitabine;Paclitaxel;Rucaparib;Abiraterone;Ruxolitinib;Azacitidine
262 Phase II Study of SB1518 for Patients With Myelodysplastic Syndrome (MDS) Terminated NCT01436084 Phase 2 SB1518
263 A Phase II Study of Visilizumab for the Prevention of Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation Terminated NCT00720629 Phase 2 Visilizumab;Tacrolimus;Methotrexate;Antithymocyte globulin (ATG);Tacrolimus;Methotrexate
264 Pacritinib Prior to Transplant for Patients With Myeloproliferative Neoplasms (MPN) Terminated NCT02410551 Phase 2 Pacritinib;Busulfan;Fludarabine
265 Transplantation Of Umbilical Cord Blood From Unrelated Donors In Patients With Haematological Diseases Using A Myeloablative Conditioning Regimen Terminated NCT02310997 Phase 2 Cyclophosphamide;Busulfan;Melphalan;Fludarabine
266 A Phase II, Prospective, Non-Controlled, Open-Label, Efficacy, Safety, Pharmacokinetic, and Pharmacodynamic Study of Pacritinib in Asian Subjects With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis or Post- Essential Thrombocythemia Myelofibrosis Withdrawn NCT02584777 Phase 2
267 Phase II Study Evaluating Busulfan and Fludarabine as Preparative Therapy in Adults With Hematopoietic Disorders Undergoing Matched Unrelated Donor Stem Cell Transplantation Withdrawn NCT00301912 Phase 2 busulfan;fludarabine phosphate;methotrexate;tacrolimus
268 Open Label Phase 2 Single Agent Study of PAT-1251 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF) Withdrawn NCT04054245 Phase 2 LOXL2 Inhibitor PAT-1251
269 Creation of Bone Marrow Microenvironment for Treatment of MDS in Conjunction With Allogeneic Stem Cell Transplantation Withdrawn NCT00148980 Phase 2
270 Multi-Center, Prospective, Randomized, Double-Blinded, Controlled Clinical Trial to Evaluate the Safety and Effectiveness of an Antimicrobial Catheter Lock Solution in Maintaining Catheter Patency and Preventing Catheter Related Blood Stream Infections (CRBSI) Withdrawn NCT01101412 Phase 1, Phase 2 Edetate Calcium Disodium;Ethanol;Trimethoprim-sulfamethoxazole
271 T Cell-Reduced Unrelated Donor Allogeneic Peripheral Blood Stem Cell Transplantation With Pentostatin and Low-Dose Total Body Irradiation Withdrawn NCT00816413 Phase 1, Phase 2 cyclosporine;mycophenolate mofetil;pentostatin
272 Emergency Access to C.V. pp65 / IE-1 Specific Cytotoxic T Lymphocytes for Recipients of Allogeneic Stem Cell Transplants With Persistant or Therapy Refractory Infections Unknown status NCT00769613 Phase 1
273 Phase I Trial of High Dose Chemotherapy Using Amifostine for In-Vivo Protection of GM-CSF Primed Progenitor Cells Unknown status NCT00004036 Phase 1 amifostine trihydrate;carboplatin;cyclophosphamide
274 A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies Completed NCT00807677 Phase 1 TAK-901
275 Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Adults and Children With Relapsed or Refractory Acute Leukemias Completed NCT00293410 Phase 1 clofarabine;cyclophosphamide
276 A Phase I Open-Label Study of S-Trans, Trans-Farnesylthiosalicylic Acid (FTS) Administered on Days 1 to 21 of a 28 Day Cycle in Patients With Advanced Hematologic Malignancies Completed NCT00867230 Phase 1 FTS
277 A Phase 1, Open-label, Dose-escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Orally Administered TG101348 in Patients With Primary, Post-polycythemia Vera, or Post-essential Thrombocythemia Myelofibrosis Completed NCT00631462 Phase 1 TG101348
278 Nonmyeloablative Bone Marrow Transplants in Hematologic Malignancies: Dose Finding Study for Post-Transplant Immunosuppression Completed NCT00255710 Phase 1 cyclophosphamide;fludarabine phosphate;mycophenolate mofetil;tacrolimus
279 Phase I Study of T Cell Depleted (TCD) Partially Matched Related Donor (PMRD) Hematopoietic Stem Cell Transplantation for High Risk Hematologic Diseases Using Intense Pre and Post Transplant Immunosuppression and Megadose CD34 "Veto" Cells Completed NCT00004904 Phase 1 cladribine;cyclophosphamide;etoposide;methylprednisolone;tacrolimus
280 A Phase I Trial of EMD 121974 in Patients With Advanced or Metastatic Cancer Completed NCT00004258 Phase 1 cilengitide
281 A Phase I Trial of Recombinant Human Interleukin-12 After High-Dose Therapy and Autologous Hematopoietic Stem Cell Support Completed NCT00003107 Phase 1
282 A Phase IA Trial of Combined Murine IgG Monoclonal Anti-Transferrin Receptor Antibodies E2.3 and A27.15 in Cancer Patients Completed NCT00003082 Phase 1
283 A Phase I Study of Triciribine Phosphate Monohydrate (TCN-PM, VD-0002) in Adult Patients With Advanced Hematologic Malignancies Completed NCT00642031 Phase 1 Triciribine
284 A PhaseI/II, Open Label Multi-Centre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the JAK2 Inhibitor AZD1480 Administered Orally to Patients With Primary Myelofibrosis (PMF) and Post-Polycythaemia Vera/Essential Thrombocythaemia Myelofibrosis (Post-PV/ET MF Completed NCT00910728 Phase 1 AZD1480
285 A Phase 1b Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Idelalisib in Subjects Receiving Ruxolitinib as Therapy for Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis With Progressive or Relapsed Disease Completed NCT02436135 Phase 1 Idelalisib;Ruxolitinib
286 Augmenting Bone Marrow With CD34 Enriched Peripheral Blood Hematopoietic Stem Cells for Allogeneic Transplantation of Hematologic Malignancies Completed NCT00004232 Phase 1 cyclosporine;methylprednisolone;prednisone
287 A Phase 1 Study of MKC-1 in Patients With Refractory Hematologic Malignancies Completed NCT00506402 Phase 1 MKC-1
288 A Phase I Clinical Study of CWP232291 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia-2, Myelodysplastic Syndrome Having Failed Hypomethylating Treatment, and High-Risk Myelofibrosis Completed NCT01398462 Phase 1 CWP232291
289 Blinded Cross-over Bioequivalence Trial of Luitpold Azacitidine Versus Vidaza® in Patients With Myelodysplastic Syndrome, Myelofibrosis, Chronic Myeloid Leukemia or Chronic Lymphocytic Leukemia Completed NCT01290302 Phase 1 Luitpold Azacitidine;Vidaza®
290 A Phase IB/III, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Vismodegib in Combination With Ruxolitinib Versus Placebo and Ruxolitinib in Patients With Intermediate- or High-Risk Myelofibrosis Completed NCT02593760 Phase 1 Ruxolitinib;Vismodegib
291 A Phase 1 Open Label, Single Dose, Parallel-Group Study to Determine the Pharmacokinetics of Pacritinib in Patients With Impaired Hepatic Function in Comparison With Healthy Subjects Completed NCT02765724 Phase 1 Pacritinib
292 Prolonged Infusion Compared to Standard Infusion Cefepime as Empiric Treatment of Febrile Neutropenia: A Pilot Study Completed NCT01484015 Phase 1 cefepime hydrochloride
293 A Phase 1 Study of LY2784544 in Patients With JAK2 V617F-Positive Myeloproliferative Disorders Completed NCT01134120 Phase 1 LY2784544
294 A Phase 1 Open-Label, Single-Dose, Parallel-Group Study to Determine the Pharmacokinetics of Pacritinib in Patients With Mild, Moderate, and Severe Renal Impairment and End-Stage Renal Disease (ESRD) Compared to Healthy Subjects Completed NCT02807077 Phase 1 Pacritinib
295 A Phase I Pharmacokinetic Study of STI571 in Patients With Advanced Malignancies and Varying Levels of Liver Dysfunction Completed NCT00025415 Phase 1 imatinib mesylate
296 A Phase I Study of JAK Inhibition (INCB018424) in Children With Relapsed or Refractory Solid Tumors, Leukemias, and Myeloproliferative Neoplasms Completed NCT01164163 Phase 1 ruxolitinib phosphate
297 Phase I/Ib Study of Azacitidine or Decitabine With Hedgehog Pathway Inhibition in Myeloid Malignancies Completed NCT02129101 Phase 1 Azacitidine;Decitabine;Sonidegib
298 A Phase I Study of 5-AZA-2'-Deoxycytidine and Depsipeptide in Patients With Relapsed/Refractory Leukemia, Myelodysplastic Syndromes, or Myeloproliferative Disease Completed NCT00114257 Phase 1 decitabine;romidepsin
299 Phase I Pharmacology Study Of Oral And Intravenous BCX-1777 In Patients With Refractory T-Cell And Non-T-Cell Malignancies Completed NCT00073944 Phase 1 forodesine hydrochloride
300 Phase I Trial of Intravenous Fenretinide (4-HPR) for Patients With Hematologic Malignancies Completed NCT00104923 Phase 1 fenretinide
301 A Dose Finding Study of R115777 (NSC 702818) in Patients With Advanced Hematologic Malignancies Completed NCT00005967 Phase 1 tipifarnib
302 A Phase I Study of the Biologic and Clinical Effects of 5-AZA-2'Deoxycytidine (DAC) in Patients With Advanced Malignancies Completed NCT00002980 Phase 1 decitabine
303 A Phase 1/Pharmacokinetic Study of Sunitinib in Patients With Cancer Who Also Have HIV and Are on HAART Therapy Completed NCT00890747 Phase 1 sunitinib malate
304 Phase I Study of Vorinostat (Suberoylanilide Hydroxamic Acid, or SAHA) in Combination With Cytosine Arabinoside (Ara-C) and Etoposide for Patients With Relapsed and/or Refractory Acute Leukemias, Myelodysplasias and Myeloproliferative Disorders Completed NCT00357305 Phase 1 vorinostat;cytarabine;etoposide
305 A Phase I Study of PXD101 in Combination With Azacitidine (5-Aza) for Advanced Hematologic Malignancies Completed NCT00351975 Phase 1 Belinostat;Azacitidine
306 Total Body Irradiation With Fludarabine Conditioning Followed by Transplantation With Combined Umbilical Cord Blood Grafts Completed NCT00606437 Phase 1
307 Donor Natural Killer Cell Infusion for the Prevention of Relapse or Graft Failure After HLA-Haploidentical Familial Donor Bone Marrow Transplantation-A Phase I Study Completed NCT00569283 Phase 1
308 Rasburicase to Prevent Graft -Versus-Host Disease Completed NCT00513474 Phase 1 busulfan;cyclophosphamide;cyclosporin-A;etoposide;methotrexate;rasburicase;sirolimus;tacrolimus;fludarabine;allopurinol
309 A Phase I Trial to Examine the Safety, Clinical, Immunologic and Virologic Effects of CMV pp65 Specific Cytotoxic T Lymphocytes for Recipients of Allogeneic Stem Cell Transplants With Persistent or Therapy Refractory Infections Completed NCT00509691 Phase 1
310 Pilot Study Of Multiple Umbilical Cord Blood Unit Transplantation Following Non-Myeloablative Conditioning In Patients With Hematologic Disorders Or Severe Aplastic Anemia Completed NCT00054236 Phase 1 cyclophosphamide;fludarabine phosphate;methylprednisolone
311 A Phase I Clinical And Pharmacological Study Of Pyroxamide (NSC 696085) In Patients With Advanced Malignancies Completed NCT00042900 Phase 1 pyroxamide
312 Reduced Intensity Conditioning Regimen for Haplo-identical Family Donor Stem Cell Transplants for Hematologic Malignancies With Delayed Add-back of Non-alloreactive T Cells Completed NCT00104975 Phase 1 fludarabine phosphate;melphalan;tacrolimus;thiotepa
313 T-Cell Depleted, Reduced-Intensity Allogeneic Stem Cell Transplantation From Haploidentical Related Donors For Hematologic Malignancies Completed NCT00080925 Phase 1 cyclophosphamide;cyclosporine;cytarabine;doxorubicin hydrochloride;etoposide;fludarabine phosphate;prednisone;vincristine sulfate
314 Phase I Trial of Interleukin-12 Followed by Interferon-Alpha Completed NCT00003451 Phase 1
315 A Phase I Study of Low Dose Continuous Infusion Topotecan in Combination With 5-Fluorouracil and Leucovorin for Advanced Malignancies Completed NCT00003331 Phase 1 fluorouracil;leucovorin calcium;topotecan hydrochloride
316 Donor Mesenchymal Stem Cell Infusion for Treatment of Graft Versus Host Disease: A Phase I Trial Completed NCT00361049 Phase 1
317 Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Pilot Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source Completed NCT02167958 Phase 1 Fludarabine;Cyclophosphamide;Mesna;Tacrolimus;Mycophenolate;G-CSF
318 A Phase 1 Study To Evaluate The Safety, Pharmacokinetics, And Pharmacodynamics Of PF 04449913, An Oral Hedgehog Inhibitor, Administered As Single Agent In Select Hematologic Malignancies Completed NCT00953758 Phase 1 PF-04449913
319 Open Label Phase I Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemia (With Pilot Feasibility Study in Combination With Pegylated Interferon Alfa 2a for Patients Who do Not Respond to the Single Agent at Each Dose Level) Completed NCT02407080 Phase 1 RG7388;Pegasys
320 A Phase I Study of Obatoclax Mesylate (GX15-070MS) in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Chronic Myeloid Leukemia (CML)in Myeloid Blast Phase, Myelofibrosis, Previously-Treated Chronic Lymphocytic Leukemia (CLL), or Aplastic Anemia Completed NCT00438178 Phase 1 Obatoclax mesylate (GX15-070MS)
321 Phase I Open-Label, Sequential Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AC220 When Administered Daily to Patients With Relapsed or Refractory Acute Myeloid Leukemia Completed NCT00462761 Phase 1 AC220
322 A Phase I Open-Label Study to Assess the Safety, Tolerability and Preliminary Efficacy of TH-302, a Hypoxia-Activated Prodrug, in Patients With Advanced Leukemias Completed NCT01149915 Phase 1 TH-302
323 Phase I Study of Ruxolitinib for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) Completed NCT01895842 Phase 1 Ruxolitinib
324 Phase 1b Study of PU-H71 for the Treatment of Subjects With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Treated With Ruxolitinib Recruiting NCT03935555 Phase 1 PU-H71
325 Phase I Study of AVID200 in Patients With Myelofibrosis (Myeloproliferative Neoplasms Research Consortium [MPN-RC] 118) Recruiting NCT03895112 Phase 1 AVID200
326 A Phase 1, Open-Label, Multicenter, Dose Escalation and Expansion Study of PRT811 in Subjects With Relapsed/Refractory Myelofibrosis, Advanced Solid Tumors and Recurrent High-Grade Gliomas Recruiting NCT04089449 Phase 1 PRT811
327 Pevonedistat in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis Recruiting NCT03386214 Phase 1 Pevonedistat;Ruxolitinib
328 A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT Recruiting NCT03912064 Phase 1 Ipilimumab
329 Pilot Open-Label Study of Safety and Efficacy of Ruxolitinib Given Peri-Transplant During Reduced Intensity Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients With Myelofibrosis Recruiting NCT02917096 Phase 1 Fludarabine;Fludarabine Phosphate;Melphalan;Ruxolitinib;Ruxolitinib Phosphate;Sirolimus;Tacrolimus
330 Haploidentical Donor Hematopoietic Stem Cell Transplantation Recruiting NCT02660281 Phase 1 Fludarabine;Pre-Stem Cell Infusion Cyclophosphamide;Pre-Stem Cell Infusion Mesna;Busulfan;Melphalan;Post-Stem Cell Infusion Cyclophosphamide;Post-Stem Cell Infusion Mesna;Thiotepa
331 A Pilot Study of Reduced Intensity HLA-Haploidentical Hematopoietic Cell Transplantation With Post-Transplant Cyclophosphamide in Patients With Advanced Myelofibrosis Recruiting NCT03118492 Phase 1 Cyclophosphamide;Fludarabine;Melphalan;Mycophenolate Mofetil;Tacrolimus
332 Phase I Study of MEK Inhibitor Selumetinib in Combination With Azacitidine in Patients With Higher Risk Chronic Myeloid Neoplasia: MDS, MDS/MPNs, and Myelofibrosis Recruiting NCT03326310 Phase 1 Azacitidine;Selumetinib
333 A Phase 1 Open-Label Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Alone and in Combination With Ruxolitinib in Asian Subjects With Myeloproliferative Neoplasm Recruiting NCT04041050 Phase 1 Navitoclax;Ruxolitinib
334 Phase I Trial to Evaluate the Safety and Feasibility of CK0801 in Treatment of Bone Marrow Failure Syndrome Recruiting NCT03773393 Phase 1
335 A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients Recruiting NCT03110822 Phase 1 Ruxolitinib Oral Tablet [Jakafi];Lenalidomide;Methylprednisolone
336 A Phase 1b, Open-label, Multi-center, Single Arm, Dose Finding Study to Assess Safety and Pharmacokinetics of the Oral Combination of Panobinostat and Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-polycythemia Vera-myelofibrosis (PPV-MF) or Post-essential Thrombocythemia-myelofibrosis (PET-MF) Active, not recruiting NCT01433445 Phase 1 panobinostat;ruxolitinib
337 A Phase Ib, Multi-center, Open-label, Dose-escalation Study of PIM447 in Combination With Ruxolitinib (INC424) and LEE011 Administered Orally in Patients With Myelofibrosis Active, not recruiting NCT02370706 Phase 1 PIM447;Ruxolitinib;LEE011
338 Study of the JAK Inhibitor Ruxolitinib Administered Orally to Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia-Myelofibrosis (PET-MF) Active, not recruiting NCT01317875 Phase 1 Ruxolitinib
339 TGR-1202 + Ruxolitinib in Subjects With Myelofibrosis, MDS/MPN, or Polycythemia Vera Resistant to Hydroxyurea Active, not recruiting NCT02493530 Phase 1 TGR-1202;ruxolitinib
340 A Phase-1-first in Man Study in Patients With CALR-mutant Myeloproliferative Neoplasms by Vaccinating With CALR Exon 9 Mutant Peptide Active, not recruiting NCT03566446 Phase 1
341 A Phase Ib Study of Ruxolitinib in Combination With PU-H71 for the Treatment of Subjects With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV MF), and Post-EssentialThrombocythemia MF (Post-ET MF) Active, not recruiting NCT03373877 Phase 1 PU-H71;Ruxolitinib
342 A Phase I Trial to Evaluate Safety and Immunogenicity of a Cytomegalovirus Peptide Vaccine Co-Injected With PF-03512676 Adjuvant in Recipients of Allogeneic Hematopoietic Stem Cell Transplant Active, not recruiting NCT01588015 Phase 1
343 A Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haploidentical Peripheral Blood Stem Cell Transplantation Active, not recruiting NCT03018223 Phase 1 Fludarabine;Busulfan;Cyclophosphamide;Sirolimus (SIR);Mycophenolate mofetil (MMF);Granulocyte-colony stimulating factor (G-CSF)
344 A Phase 1, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients With Intermediate-2 and High-Risk Primary or Secondary Myelofibrosis Not yet recruiting NCT04176198 Phase 1 TP-3654
345 Umbilical Cord Blood Transplant With Co-Infusion of T Regulatory Cells Terminated NCT00376519 Phase 1 cyclophosphamide;cyclosporine;fludarabine phosphate;mycophenolate mofetil
346 Phase I Study of 12-O-tetradecanoylphorbol-13-acetate (TPA) in Patients With Refractory Hematologic Malignancies/Bone Marrow Disorders Terminated NCT00004058 Phase 1 tetradecanoylphorbol acetate
347 Phase I Study of GC1008 in Patients With Primary Myelofibrosis (PMF), Post-polycythemia Vera/Essential Thrombocythemia Related Myelofibrosis (Post-PV/ET MF) Terminated NCT01291784 Phase 1
348 A Phase Ib, Open-label, Multi-center, Two-arm, Dose-finding Study to Assess Safety and Efficacy of the Oral Combination or INC424 (INC424) and BKM120 in Patients With Primary Myelofibrosis (PMF), Postpolycythemia Vera-myelofibrosis (PPV-MF), or Post-essential Thrombocythemia-myelofibrosis (PET-MF) Terminated NCT01730248 Phase 1 INC424;BKM120
349 A Phase 1 Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL019 Administered to Subjects With Myelofibrosis Terminated NCT00522574 Phase 1 XL019
350 A Phase I Study of Oral Arsenic Trioxide With or Without Ascorbic Acid in Adults With Myelofibrosis Terminated NCT01014546 Phase 1 Arsenic Trioxide
351 Pilot Safety and Feasibility Trial of Mycophenolate and Sirolimus for Prevention of GVHD in Mismatched Unrelated and Related Donor Hematopoietic Stem Cell Transplantation for Hematologic Malignancies Terminated NCT02728700 Phase 1 Mycophenolate Mofetil;Sirolimus
352 Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute Leukemias Terminated NCT00852709 Phase 1 Clofarabine;Cyclophosphamide
353 A Phase I Study of Compound 506U78 (NSC #686673) in Patients With Hematologic Malignancies and Renal or Hepatic Impairment Terminated NCT00004239 Phase 1 Compound 506U78
354 Phase I Study of Escalating Doses of Radiation Therapy Using Helical Tomotherapy in Combination With Fludarabine (FLU) and Melphalan (MEL) as a Preparative Regimen for Allogeneic Hematopoietic Stem Cell (HSC) Transplantation in Patients With Advanced and Hematological Malignancies Who Are Not Eligible for Fully Myeloablative Regimen Terminated NCT00800150 Phase 1 fludarabine phosphate;melphalan
355 A Phase 1, Single Arm, Single Center Pilot Study of Medi4736, an Anti-Pdl1 Therapy, for Patients With Myelofibrosis Withdrawn NCT02871323 Phase 1
356 A Pilot Study of Pacritinib in Combination With Low Dose Decitabine in Patients With Intermediate-High Risk Myelofibrosis or MPN/MDS Syndromes Withdrawn NCT02564536 Phase 1 Pacritinib;Decitabine
357 A Phase I Trial of Ruxolitinib Combined With Tacrolimus and Sirolimus as Acute Graft-versus-Host Disease (aGVHD) Prophylaxis During Reduced Intensity Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis Withdrawn NCT02528877 Phase 1 Fludarabine Phosphate;Melphalan;Ruxolitinib Phosphate;Sirolimus;Tacrolimus
358 Assessment of Labile Plasma Iron (LPI) as an Alternative Parameter for Iron Overload in MDS and Primary Myelofibrosis Patients With Iron Overload and Its Correlations With the Classical Iron Overload Parameters. Unknown status NCT01331603
359 A Case Control Study of the Prevalence of Pulmonary Hypertension in Patients With Myeloproliferative Diseases, and Correlation Between Patients Epidemiologic and Clinical Status and the Development of Pulmonary Hypertension. Unknown status NCT01884974
360 Myeloproliferative Neoplasms and Bone Structure Unknown status NCT01816022
361 Functional and Morphological Cardiac Changes in Myeloproliferative Neoplasms Unknown status NCT03177928
362 Myeloproliferative Neoplasms: an In-depth Case-control Study Unknown status NCT01831635
363 Non-myeloablative Allogeneic Stem Cell Transplantation With Match Unrelated Donors for Treatment of Hematologic Malignancies and Renal Cell Carcinoma and Aplastic Anemia Unknown status NCT00295997 busulfan;cyclophosphamide;fludarabine phosphate;methotrexate;mycophenolate mofetil;tacrolimus
364 A Prospective Open-Label Pilot Trial of PS-341 (Bortezomib; VELCADE) for the Therapy of Symptomatic Advanced Myeloproliferative Disorders Completed NCT00437086 Early Phase 1 PS-341
365 Research Tissue Bank Completed NCT00666549
366 Molecular Biology of Familial Myeloproliferative Disorders Completed NCT00666289
367 Correlative Biomarker Study for MPD-RC Treatment Studies in the Philadelphia Chromosome Negative MPD Completed NCT00665067
368 Molecular Changes and Biomarkers in Chronic Myeloproliferative Disorders Completed NCT00433862
369 Adjustment to Illness by Survival Rates in Allogeneic Bone Marrow Transplant (BMT): The Relative Importance of Lay Care-Partner Support Completed NCT00281814
370 A Randomized Trial of the Effect of a Walking Regimen on the Functional Status of Adult Allogeneic Donor Bone Marrow Transplant Patients Completed NCT00445731
371 Immunomodulation by Ultraviolet B-Irradiation (UVB) to Facilitate Allogeneic Stem Cell Transplantation for Treatment of Hematologic Malignancies Completed NCT00068523 cyclophosphamide;cyclosporine;fludarabine phosphate;methylprednisolone
372 Multi-Site Randomized Clinical Trial Comparing Standard Recovery Preparation to Extended Recovery Preparation to Enhance Long Term Function After Marrow or Stem Cell Transplant Completed NCT00049465
373 Emotional Needs of Caregivers and Patient/Spouse Couples During Hematopoietic Stem Cell Transplantation (HSCT) Completed NCT00082654
374 A Cyclophosphamide/Fludarabine/Total Body Irradiation Preparative Regimen for Patients With Hematological Malignancy Receiving Unrelated Donor Umbilical Cord Blood Transplantation Completed NCT00290641 cyclophosphamide;cyclosporine;fludarabine phosphate;mycophenolate mofetil
375 Survival in Allogeneic Bone Marrow Transplantation: The Relative Importance of Inpatient Lay Care-Partner Support Completed NCT00281801
376 A Pilot Study of Aprepitant vs. Placebo Combined With Standard Antiemetics for the Control of Nausea and Vomiting During Hematopoietic Cell Transplatation(HCT) Completed NCT00248547 aprepitant;dexamethasone;ondansetron;placebo
377 Polycythemia Vera, Myelofibrosis and Essential Thrombocythemia: Identification of PV, MF & ET Genes Completed NCT00715247
378 Chart Review of Reduced Intensity Conditioning (RIC) Allogeneic Transplants in Elderly Patients With Myelofibrosis. Completed NCT00723333
379 Etude de l'efficacité et de la tolérance de l'interféron-pégylé Dans Les myélofibroses Completed NCT02910258
380 Role of the Circulating Procoagulants Microparticles in the Hypercoagulability of Chronic Philadelphia Negative Myeloproliferative Neoplasms Completed NCT02862366
381 Cyclophosphamide Followed by Intravenous Busulfan as Conditioning for Hematopoietic Cell Transplantation in Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome. Completed NCT00445744 cyclophosphamide;busulfan;tacrolimus;methotrexate
382 Prospective Pilot Trial of Arsenic Trioxide (Trisenox®) in Combination With Cytosine Arabinoside in Patients With Advanced or Transformed Myelofibrosis Completed NCT00572065 Early Phase 1 arsenic trioxide;cytarabine
383 Genetic Analysis of Gray Platelet Syndrome Completed NCT00069680
384 A Pilot Study to Evaluate the Potential Efficacy of Lithium Carbonate for Stimulation of Intestinal Recovery In Patients With Acute Graft-versus-host Disease (GVHD) Completed NCT00408681 lithium carbonate
385 A Preliminary Study to Evaluate the Effects of Palifermin in Patients at Risk of Chronic Graft-versus-host Disease Completed NCT01233921
386 Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies Completed NCT01499147 fludarabine/busulfan;fludarabine/ melphalan;ATG
387 A Pilot Trial Of Reduced Intensity Allogeneic Stem Cell Transplantation With Fludarabine, Melphalan, And Low Dose Total Body Irradiation Completed NCT00856388 fludarabine phosphate;melphalan
388 Music Therapy for Distress During Autologous Stem Cell Transplantation: A Randomized Trial Completed NCT00014482
389 Allogeneic Hematopoietic Stem Cell Transplantation for Induction of Mixed Hematopoietic Chimerism in Patients Infected With Human Immunodeficiency Virus-1 Using a Non-Marrow Ablative Conditioning Regimen Containing Total Body Irradiation in Combination With Post-Transplant Immunosuppression With Cyclosporine and Mycophenolate Mofetil Completed NCT00112593 fludarabine phosphate;cyclosporine;mycophenolate mofetil
390 Molecular Study of Factors Involved in JAK-STAT Signalling Pathway in Familial Myeloproliferative Disorders Completed NCT00873574
391 The TOUCH Project: Reducing Distress and Promoting Quality of Life Via Caregiver Massage of Children Undergoing Treatment for Cancer Completed NCT01053494
392 Modified Preemptive CMV Management Strategy After Allogeneic Hematopoietic Cell Transplantation and Laboratory Correlation With Innate Immune Function Completed NCT01199562 ganciclovir;valganciclovir;foscarnet sodium
393 A Randomized, Placebo-Controlled, Blinded Study Of Acupuncture Therapy In Mucositis-Related Pain In Patients Undergoing Hematopoietic Stem Cell Transplantation Completed NCT00060021
394 Use Of Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) To Mobilize Donor Peripheral Blood Stem Cells Along With GM-CSF Administration Post Allogeneic Transplant - A Pilot Study Completed NCT00053157
395 Randomized Trial Of Safety And Tolerability Of Intravenous/Oral Voriconazole Versus Intravenous/Oral Itraconazole For Long-Term Antifungal Prophylaxis In Allogeneic Hematopoietic Stem Cell Transplant Recipients Completed NCT00079222 itraconazole;voriconazole
396 Low-Dose Allogeneic Peripheral Blood Stem Cell Transplantation for High-Risk Low Grade Hematologic Malignancies Completed NCT00296023 busulfan;fludarabine phosphate;methotrexate;tacrolimus
397 Pilot Study Evaluating Aprepitant (MK-869) for Prevention of Nausea & Vomiting Secondary to High Dose Cyclophosphamide Administered to Patients Underging Undergoing Peripheral Hematopoietic Progenitor Cell Mobilization Prior to Autologous Transplantation Completed NCT00293384 Aprepitant;Cyclophosphamide;Dexamethasone;Granisetron hydrochloride
398 Dapsone Induced Methemoglobinemia in Pediatric Hematologic Malignancy and Aplastic Anemia Completed NCT00993694 chemotherapy;dapsone
399 CMV Specific Cellular Immunity in Recipients of Allogeneic Bone Marrow Transplantation: Association of CMV-Specific HLA-Peptide Tetramer Binding With Cytotoxic T-Cell Function, CMV Infection and Other Clinical Events Completed NCT00716911 ganciclovir
400 Influenza Specific Humoral and Cellular Immunity After Vaccination in Recipients of Allogeneic and Autologous Hematopoietic Stem Cell Transplantation Completed NCT00964821
401 Fungemia Survey in Cancer Patients Completed NCT00445952
402 Reduced Intensity Allogeneic Hematopoietic Cell Transplantation for Patients With Hematological Diseases Completed NCT00453206
403 Use of Music to Reduce Anxiety & Perceived Pain for Adult Patients With Hematological Malignancies Undergoing Bone Marrow Biopsy Completed NCT00376922
404 A Standardized Nursing Intervention Protocol for HCT Patients Completed NCT00951626
405 Aquagenic Pruritus Among Patients With Myeloproliferative Syndromes (in English) Prurit Aquagénique Dans Les SYndromes MyéloProLifEratifs (in French) Completed NCT03688490
406 Screening for Asymptomatic Portal Vein Thrombosis and Portal Hypertension in Patients With Philadelphia Negative Myeloproliferative Neoplasms Completed NCT01816256
407 Secondary Cancers in Myeloproliferative Neoplasms (MPN-K Study) Completed NCT03745378
408 A Randomised Trial to Compare Aspirin vs Hydroxyurea/Aspirin in 'Intermediate Risk' Primary Thrombocythaemia and Aspirin Only With Observation in 'Low Risk'Primary Thrombocythaemia Completed NCT00175838 Hydroxyurea;Aspirin
409 Clinical and Pathophysiological Investigations Into Erdheim-Chester Disease Completed NCT01417520
410 A Pilot Study of Online Yoga to Improve Symptom Burden (i.e., Fatigue) and Quality of Life in MPN Patients Completed NCT03503838
411 Pilot Study for the Development of a Non-invasive Diagnostic Score to Differentiate Between Essential Thrombocythemia, Premyelofibrosis and Myelofibrosis Recruiting NCT03869476
412 Defining the Molecular Risk in Israeli Patients With Secondary Compared to Primary Myelofibrosis Recruiting NCT03402399
413 Observational, Retrospective and Prospective Study on the Use of Ruxolitinib in Myelofibrosis Patients in Lombardy, Italy Recruiting NCT03959371 Ruxolitinib
414 Aquagenic Pruritus in Myeloproliferative Neoplasms Recruiting NCT04018209
415 Observatoire Brestois Des Néoplasies Myéloprolifératives Recruiting NCT02897297
416 European Registry for Myeloproliferative Neoplasms (MPNs) - Update of ERNEST Study Recruiting NCT04153305
417 Quantitative MRI for Myelofibrosis - MRI Parameters as Biomarkers for Analyzing Extent of Disease and Measuring Response to Treatment Recruiting NCT01973881
418 Clinical and Molecular Epidemiology of Myeloproliferative Neoplasms (MPNs) Recruiting NCT02760238
419 A Pilot Study of Reduced Intensity HLA-Haploidentical Hematopoietic Cell Transplantation With Post-Transplant Cyclophosphamide in Patients With Advanced Myelofibrosis Recruiting NCT03426969 Early Phase 1 Cyclophosphamide;Fludarabine Phosphate;Melphalan;Mycophenolate Mofetil;Tacrolimus
420 Prospective Assessment of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis Recruiting NCT02934477
421 Clinical and Therapeutic Impact of Molecular Markers in Myeloproliferative Neoplasms (CTIM3) Recruiting NCT02823210
422 A Study of 18F-FLT Positron Emission Tomography/Computed Tomography (PET/CT) Imaging in Cases of Prefibrotic/Early Primary Myelofibrosis (PMF) and Essential Thrombocythemia (ET) Recruiting NCT03116542
423 Cardiovascular Fibrosis in Idiopathic Pulmonary Fibrosis Recruiting NCT04177251
424 Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for the Treatment of Hematological Diseases Recruiting NCT01962636 Fludarabine;Cyclophosphamide;Cyclosporine A;Mycophenylate mofetil
425 Registry of Philadelphia-Negative Myeloproliferative Neoplasms Recruiting NCT02380378
426 Carolina Senior: UNC Registry for Older Cancer Patients Recruiting NCT01137825
427 Tissue Procurement For Hematolymphoid Conditions Recruiting NCT01137643
428 Use of [F-18] FLT for Imaging With Positron Emission Tomography (PET) Recruiting NCT00935090
429 Exploring the Mechanisms of Resistance of Stem Cells Myeloproliferative Opposite of Tyrosine Kinase Inhibitors in 3d Model Niche Endosteal Recruiting NCT02766153
430 A Multicenter, Open-Label, Pilot Study of Alisertib (MLN8237), a Novel Inhibitor of Aurora Kinase A, in Adult Patients With Relapsed/Refractory Acute Megakaryoblastic Leukemia or Myelofibrosis (Including Primary and Post-Essential/Post-Polycythemic Myelofibrosis) Active, not recruiting NCT02530619 Alisertib
431 Identification of Mechanisms in the Erythroid Response in Patients With Myelodysplasia Undergoing Chelation Therapy Active, not recruiting NCT01956799
432 Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients With Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy Active, not recruiting NCT02953704
433 Patients With Myelofibrosis Treated With Combination of Janus Kinase 2 Inhibitor and Erythropoiesis-stimulating Agent. A French Observational Study. Active, not recruiting NCT03208803
434 A Pharmacokinetic Study of Pemetrexed in the Cerebrospinal Fluid of Patients With Leptomeningeal Metastases Active, not recruiting NCT00424242 Early Phase 1 Pemetrexed
435 Compassionate Use of Fedratinib for Patients Who Have Previously Received TG101348, SAR302503 or Fedratinib Available NCT03723148 Oral Fedratinib
436 Expanded Access to Navitoclax Available NCT03592576 Navitoclax
437 Registry of Patients With Myeloproliferative Neoplasms (MPNs) in Taiwan -Taiwan MPN Working Group Enrolling by invitation NCT03618485
438 Evaluation of New Biomarkers of Thrombosis in Myeloproliferative Neoplasms Not yet recruiting NCT04177576
439 Risk Factors and Predictors of Thrombosis in Patients With Philadelphia Negative Myeloprolferative Neoplasms Not yet recruiting NCT03599700
440 A Pilot Study of Double Cord Blood Stem Cell Transplantation in Patients With Hematologic Malignancies No longer available NCT00423826 Busulfan;Cytarabine;Fludarabine phosphate;mycophenolate mofetil;tacrolimus
441 Reversible Secondary Myelofibrosis or Clonal Myeloproliferative Disorder Terminated NCT00722254
442 A Pilot Study of Using Filgrastim-Primed Bone Marrow in Human Leukocyte Antigen (HLA) Matched Related Donor Allogenetic Bone Marrow Transplantation for Patients With Hematologic Malignancies and Non-Malignancies Terminated NCT00253552 busulfan;cyclophosphamide;cyclosporine;etoposide;methotrexate
443 Transplantation of Umbilical Cord Blood From Related and Unrelated Donors Terminated NCT00290628 anti-thymocyte globulin;busulfan;cyclophosphamide;cyclosporine;filgrastim;melphalan;methylprednisolone;mycophenolate mofetil
444 A Study of 18F-FLT Positron Emission Tomography (PET)/Computed Tomography Imaging in Pediatrics With Myeloproliferative Neoplasms Terminated NCT03121599
445 Non-Myeloablative Conditioning and Unrelated Umbilical Cord Blood Transplantation for Children and Adults With Serious Oncohematologic Diseases Terminated NCT00255684 cyclophosphamide;cyclosporine;fludarabine phosphate;mycophenolate mofetil
446 Evaluation of Clinical Utility of the Cylex ImmunKnow Assay in Hematopoietic Cell Transplantation Terminated NCT00813501
447 Substance P Follow-up to a Pilot Study of Aprepitant vs Placebo Combined With Standard Antiemetics for the Control of Nausea and Vomiting During Hematopoietic Cell Transplantation Terminated NCT00900068
448 Pharmacokinetics of Continuous Infusion Fentanyl in Cancer Patients Terminated NCT00899951 fentanyl citrate
449 Detection of Donor-Derived DNA in Semen Samples Among Recipients of Allogeneic Hematopoietic Stem-Cell Transplants Terminated NCT01077440
450 A Randomized Comparison of Oral Methadone as a "First-Switch" Opioid Versus Opioid Switching Between Sustained-Release Morphine and Oxycodone for Oncology-Hematology Outpatients With Pain Management Problems: The "Simply Rotate" Study Terminated NCT00726830 methadone hydrochloride;morphine sulfate;oxycodone hydrochloride
451 Regulatory T Cells at Engraftment as Predictors of Acute Graft-Versus-Host Disease Outcomes in Patients Undergoing Allogeneic Stem Cell Transplantation Terminated NCT00651716
452 Radiation Sensitivity, DNA Repair, and Second Cancers. Terminated NCT00949052
453 Probiotic Enteric Regimen For Easing Complications of Transplant : A Pilot Study (PERFECT Trial) Terminated NCT00946283
454 Oral Empirical Therapy of Fever in Low-Risk Neutropenic Cancer Patients: A Prospective, Double-Blind, Randomized, Multicenter Trial Comparing Monotherapy (Single Daily Dose Moxifloxacin) With Combination Therapy (Ciprofloxacin Plus Amoxicillin/Clavulanic Acid) Terminated NCT00062231 amoxicillin-clavulanate potassium;ciprofloxacin;moxifloxacin hydrochloride
455 Targeted Single Nucleotide Polymorphisms (SNPs) to Classify Subtypes of Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Transplant. Terminated NCT00957736
456 Clinical Correlates of Immunologic Responses to the Flu Vaccine Terminated NCT00952185
457 A Pilot Study of Aprepitant Versus Ondansetron for the Treatment of Opioid Induced Nausea and Vomiting Withdrawn NCT00499668 aprepitant;ondansetron hydrochloride
458 Ruxolitinib in Combination With High Dose Therapy and Autologous Stem Cell Transplantation for Myelofibrosis Withdrawn NCT02469974 RUXOLITINIB / INC 424;Filgrastim;Busulfan
459 A Single-arm, Single Center, Pilot Study of Siltuximab, an Anti-IL6 Therapy, for Patients With Myelofibrosis Withdrawn NCT02805868 Early Phase 1
460 Long-term Safety Study of Treatment With the Thrombopoietin Agonists Eltrombopag and Romiplostim in Patients With Primary Immune Thrombocytopenia (ITP) Withdrawn NCT01443351
461 A Pilot Study to Determine the Safety and Efficacy of Incorporating Hyperbaric Oxygen Therapy Into RIC Fludarabine and Melphalan (Evomela) and Allogeneic Hematopoietic Stem/Progenitor Transplantation Withdrawn NCT03964506 Early Phase 1 Hyperbaric oxygen
462 Pilot Study of Mechanical Stimulation for Prevention of Hematopoietic Cell Transplant Associated Bone Density Loss Withdrawn NCT01558778
463 Perception of Caregiver Burden Withdrawn NCT00770419
464 Using the Transcriptome for Early Detection of Graft Versus Host Disease in Allogeneic Bone Marrow Transplantation Withdrawn NCT00898612
465 Banking DNA for Analysis of Genetic Polymorphisms in Patients With Cancer Withdrawn NCT00900120
466 Prospective, Randomized Trial Comparing Heparin and Minocycline-EDTA Flush for the Prevention of Catheter-Related Infections and Occlusions Withdrawn NCT00378781 Heparin;Minocycline-EDTA
467 Cell Cycle Regulatory Gene Study in Patients With Myeloproliferative Disorders Withdrawn NCT02663648
468 Pharmacodynamic Effects and Predictive Biomarkers of JAK/STAT Inhibition With Ruxolitinib in Operable Head and Neck Cancer: a Window Trial Withdrawn NCT02593929 Early Phase 1 ruxolitinib
469 Compassionate Use of the CliniMACS® CD34 Reagent System for Patients Requiring a Post Hematopoietic Stem Cell Transplant Boost of Donor Hematopoietic Stem Cells Withdrawn NCT01660347

Search NIH Clinical Center for Myelofibrosis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Busulfan
ruxolitinib

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Myelofibrosis cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Myelofibrosis:
Peripheral blood-derived hematopoietic stem cells for treatment of myelofibrosis
Embryonic/Adult Cultured Cells Related to Myelofibrosis:
Peripheral blood-derived hematopoietic stem cells (family)

Cochrane evidence based reviews: primary myelofibrosis

Genetic Tests for Myelofibrosis

Genetic tests related to Myelofibrosis:

# Genetic test Affiliating Genes
1 Myelofibrosis 29 CALR JAK2 MPL SH2B3

Anatomical Context for Myelofibrosis

MalaCards organs/tissues related to Myelofibrosis:

40
Bone, Myeloid, Bone Marrow, T Cells, Liver, Spleen, B Cells

Publications for Myelofibrosis

Articles related to Myelofibrosis:

(showing 6418, show less)
# Title Authors PMID Year
1
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. 54 61 56 6
15781101 2005
2
MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. 61 56 6
16868251 2006
3
MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. 61 56 6
16834459 2006
4
A gain-of-function mutation of JAK2 in myeloproliferative disorders. 61 56 6
15858187 2005
5
Neuropathy of haematopoietic stem cell niche is essential for myeloproliferative neoplasms. 56 6
25043017 2014
6
Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. 56 6
20703299 2010
7
Haematopoietic stem cell release is regulated by circadian oscillations. 56 6
18256599 2008
8
The JAK2 V617F mutation in de novo acute myelogenous leukemias. 54 61 6
16247455 2006
9
Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. 54 61 6
16325696 2005
10
JAK inhibitor in CALR-mutant myelofibrosis. 61 56
24645955 2014
11
JAK inhibitor in CALR-mutant myelofibrosis. 61 56
24645956 2014
12
Somatic mutations of calreticulin in myeloproliferative neoplasms. 61 6
24325356 2013
13
Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. 61 6
24325359 2013
14
Familial idiopathic myelofibrosis and multiple hemangiomas. 61 56
9766805 1998
15
Familial myelofibrosis. 61 56
7436463 1980
16
Effect of mutation order on myeloproliferative neoplasms. 6
25671252 2015
17
Interferon alfa therapy in CALR-mutated essential thrombocythemia. 56
25006741 2014
18
MPN patients harbor recurrent truncating mutations in transcription factor NF-E2. 56
23589569 2013
19
A novel murine model of myeloproliferative disorders generated by overexpression of the transcription factor NF-E2. 56
22231305 2012
20
Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms. 6
20404132 2010
21
MicroRNA expression profiling of megakaryocytes in primary myelofibrosis and essential thrombocythemia. 61 46
19811223 2009
22
Mutation in TET2 in myeloid cancers. 56
19474426 2009
23
The presence of JAK2V617F mutation in the liver endothelial cells of patients with Budd-Chiari syndrome. 6
19293426 2009
24
No evidence for increased prevalence of JAK2 V617F in women with a history of recurrent miscarriage. 6
19036091 2009
25
JAK2 V617F mutation in unexplained loss of first pregnancy. 6
17989398 2007
26
Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome. 6
16762626 2006
27
Case records of the Massachusetts General Hospital. Case 15-2006. A 46-year-old woman with sudden onset of abdominal distention. 6
16707754 2006
28
The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation. 6
16603627 2006
29
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. 6
15793561 2005
30
Screening for MPL mutations in essential thrombocythemia and primary myelofibrosis: normal Mpl expression and absence of constitutive STAT3 and STAT5 activation in MPLW515L-positive platelets. 54 61
20113333 2010
31
Postsplenectomy sclerosing extramedullary hematopoietic tumor with unexpected good clinical evolution: morphologic, immunohistochemical, and molecular analysis of one case and review of the literature. 54 61
20042850 2010
32
Therapeutic potential of Janus-activated kinase-2 inhibitors for the management of myelofibrosis. 54 61
20215535 2010
33
Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis. 54 61
20154217 2010
34
Clinical utility of routine MPL exon 10 analysis in the diagnosis of essential thrombocythaemia and primary myelofibrosis. 54 61
20151976 2010
35
Mutational analysis in BCR-ABL-negative classic myeloproliferative neoplasms: impact on prognosis and therapeutic choices. 54 61
20214447 2010
36
JAK2 and MPL gene mutations in V617F-negative myeloproliferative neoplasms. 54 61
19643476 2010
37
MPL W515L/K mutations in 343 Chinese adults with JAK2V617F mutation-negative chronic myeloproliferative disorders detected by a newly developed RQ-PCR based on TaqMan MGB probes. 54 61
19274616 2010
38
Therapy of myelofibrosis (excluding JAK2 inhibitors). 54 61
20178012 2010
39
Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. 54 61
20008298 2010
40
JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46/1 haplotype is associated with inferior survival. 54 61
19847199 2010
41
Activated STAT1 and STAT5 transcription factors in extramedullary hematopoietic tissue in a polycythemia vera patient carrying the JAK2 V617F mutation. 54 61
20013324 2010
42
Peripheral T-cell lymphoma presenting as myelofibrosis with the expression of basic fibroblast growth factor. 54 61
20002760 2009
43
Identification of a novel inhibitor of JAK2 tyrosine kinase by structure-based virtual screening. 54 61
19447617 2009
44
Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms. 54 61
19387008 2009
45
MPLW515L mutation in acute megakaryoblastic leukaemia. 54 61
19194467 2009
46
JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms. 54 61
19287382 2009
47
Novel strategies for patients with chronic myeloproliferative disorders. 54 61
19468275 2009
48
Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1. 54 61
19175693 2009
49
The 2008 WHO diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis. 54 61
20425436 2009
50
Extramedullary peritoneal hematopoiesis combined with tuberculosis in a patient with primary myelofibrosis. 54 61
18850308 2009
51
Oncogenic signals as treatment targets in classic myeloproliferative neoplasms. 54 61
19147089 2009
52
Molecular and genetic bases of myeloproliferative disorders: questions and perspectives. 54 61
19778861 2009
53
Therapeutic potential of JAK2 inhibitors. 54 61
20008249 2009
54
Wild-type JAK2 secondary acute erythroleukemia developing after JAK2-V617F-mutated primary myelofibrosis. 54 61
19713696 2009
55
[Effects of recombinant human thrombopoietin on stromal cells in culture in vitro]. 54 61
19099659 2008
56
Recurrent der(9;18) in essential thrombocythemia with JAK2 V617F is highly linked to myelofibrosis development. 54 61
18786436 2008
57
Novel SSBP2-JAK2 fusion gene resulting from a t(5;9)(q14.1;p24.1) in pre-B acute lymphocytic leukemia. 54 61
18618714 2008
58
The hematopoietic stem cell compartment of JAK2V617F-positive myeloproliferative disorders is a reflection of disease heterogeneity. 54 61
18612101 2008
59
A sensitive detection method for MPLW515L or MPLW515K mutation in chronic myeloproliferative disorders with locked nucleic acid-modified probes and real-time polymerase chain reaction. 54 61
18669880 2008
60
Megakaryopoiesis and platelet function in polycythemia vera and essential thrombocythemia patients with JAK2 V617F mutation. 54 61
18612778 2008
61
New mutations of MPL in primitive myelofibrosis: only the MPL W515 mutations promote a G1/S-phase transition. 54 61
18528423 2008
62
Essential thrombocythemia, polycythemia vera, and myelofibrosis: current management and the prospect of targeted therapy. 54 61
18429051 2008
63
Transforming growth factor-beta overexpression in cutaneous extramedullary hematopoiesis of a patient with myelodysplastic syndrome associated with myelofibrosis. 54 61
18342720 2008
64
Bone morphogenetic proteins are overexpressed in the bone marrow of primary myelofibrosis and are apparently induced by fibrogenic cytokines. 54 61
18349123 2008
65
Selective inhibition of JAK2-driven erythroid differentiation of polycythemia vera progenitors. 54 61
18394555 2008
66
Mesenchymal stem cells from JAK2(V617F) mutant patients with primary myelofibrosis do not harbor JAK2 mutant allele. 54 61
17706283 2008
67
Clinical implications of JAK2 mutations in myeloproliferative disorders. 54 61
18575049 2008
68
Altered SDF-1/CXCR4 axis in patients with primary myelofibrosis and in the Gata1 low mouse model of the disease. 54 61
18206727 2008
69
Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes. 54 61
17885079 2008
70
Activation loop tyrosines allow the JAK2(V617F) mutant to attain hyperactivation. 54 61
18841497 2008
71
[New insight into pathogenesis of idiopathic myelofibrosis--review]. 54 61
18088495 2007
72
Application of PRV-1 mRNA expression level and JAK2V617F mutation for the differentiating between polycytemia vera and secondary erythrocytosis and assessment of treatment by interferon or hydroxyurea. 54 61
17852451 2007
73
Advances in the molecular characterization of Philadelphia-negative chronic myeloproliferative disorders. 54 61
17906464 2007
74
JAK2 mutations and clinical practice in myeloproliferative neoplasms. 54 61
18032973 2007
75
JAK2V617F-negative ET patients do not display constitutively active JAK/STAT signaling. 54 61
17764814 2007
76
Phenotypic variations and new mutations in JAK2 V617F-negative polycythemia vera, erythrocytosis, and idiopathic myelofibrosis. 54 61
17920755 2007
77
Stem cell defects in Philadelphia chromosome negative chronic myeloproliferative disorders: a phenotypic and molecular puzzle? 54 61
18220909 2007
78
The role of Janus Kinase 2 V617F mutation in extramedullary hematopoiesis of the spleen in neoplastic myeloid disorders. 54 61
17643100 2007
79
Pivotal contributions of megakaryocytes to the biology of idiopathic myelofibrosis. 54 61
17473062 2007
80
Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. 54 61
17488875 2007
81
The gain-of-function JAK2 V617F mutation shifts the phenotype of essential thrombocythemia and chronic idiopathic myelofibrosis to more "erythremic" and less "thrombocythemic": a molecular, histologic, and clinical study. 54 61
17875526 2007
82
Clinical applications of molecular haematology: JAK2 in myeloproliferative disorders. 54 61
17907502 2007
83
Different STAT-3 and STAT-5 phosphorylation discriminates among Ph-negative chronic myeloproliferative diseases and is independent of the V617F JAK-2 mutation. 54 61
17376889 2007
84
Proteasome inhibitor bortezomib impairs both myelofibrosis and osteosclerosis induced by high thrombopoietin levels in mice. 54 61
17374740 2007
85
A higher JAK2 V617F-mutated clone is observed in platelets than in granulocytes from essential thrombocythemia patients, but not in patients with polycythemia vera and primary myelofibrosis. 54 61
17361221 2007
86
The suppressor of cytokine signalling-1 (SOCS-1) gene is overexpressed in Philadelphia chromosome negative chronic myeloproliferative disorders. 54 61
17030374 2007
87
The myeloproliferative disorder-associated JAK2 V617F mutant escapes negative regulation by suppressor of cytokine signaling 3. 54 61
17317861 2007
88
[Abnormal activation of tyrosine kinases and its role in the pathogenesis of hematological malignancies - review]. 54 61
17605888 2007
89
Anaemia characterises patients with myelofibrosis harbouring Mpl mutation. 54 61
17408465 2007
90
Clearance of the Janus kinase 2 (JAK2) V617F mutation after allogeneic stem cell transplantation in a patient with myelofibrosis with myeloid metaplasia. 54 61
17133423 2007
91
Pericyte coverage of abnormal blood vessels in myelofibrotic bone marrows. 54 61
17488682 2007
92
Different involvement of the megakaryocytic lineage by the JAK2 V617F mutation in Polycythemia vera, essential thrombocythemia and chronic idiopathic myelofibrosis. 54 61
17262192 2007
93
The first international meeting on V617F JAK2 mutation and its relevance in Philadelphia-negative myeloproliferative disorders. 54 61
16901656 2007
94
Bone marrow phospho-STAT5 expression in non-CML chronic myeloproliferative disorders correlates with JAK2 V617F mutation and provides evidence of in vivo JAK2 activation. 54 61
17255768 2007
95
JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. 54 61
17267906 2007
96
Recombinant human erythropoietin for the treatment of anaemia in patients with chronic idiopathic myelofibrosis. 54 61
17159338 2007
97
A der(18)t(9;18)(p13;p11) and a der(9;18)(p10;q10) in polycythemia vera associated with a hyperproliferative phenotype in transformation to postpolycythemic myelofibrosis. 54 61
17213018 2007
98
JAK-2 mutations and their relevance to myeloproliferative disease. 54 61
17133099 2007
99
[Molecular diagnosis of chronic myeloproliferative diseases and myelodysplastic syndromes]. 54 61
18314608 2007
100
Chronic idiopathic myelofibrosis (CIMF) resulting from a unique 3;9 translocation disrupting the janus kinase 2 (JAK2) gene. 54 61
16959246 2006
101
No influence of V617F mutation in JAK2 on outcome after allogeneic hematopoietic stem cell transplantation (HSCT) for myelofibrosis. 54 61
17162218 2006
102
Molecular mimicry in the chronic myeloproliferative disorders: reciprocity between quantitative JAK2 V617F and Mpl expression. 54 61
16912229 2006
103
Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F. 54 61
17183644 2006
104
Expression of TEL-JAK2 in primary human hematopoietic cells drives erythropoietin-independent erythropoiesis and induces myelofibrosis in vivo. 54 61
17077140 2006
105
Janus kinase 2 (V617F) mutation status, signal transducer and activator of transcription-3 phosphorylation and impaired neutrophil apoptosis in myelofibrosis with myeloid metaplasia. 54 61
16871275 2006
106
[Evaluation of V617F mutation of JAK2 in negative chromosome Philadelphia chronic myeloproliferative disorders]. 54 61
17145024 2006
107
Expression of HMGA2 in PB leukocytes and purified CD34+ cells from controls and patients with Myelofibrosis and myeloid metaplasia. 54 61
17065012 2006
108
Aberrant collagenase expression in chronic idiopathic myelofibrosis is related to the stage of disease but not to the JAK2 mutation status. 54 61
16877349 2006
109
The JAK2(V617F) tyrosine kinase mutation in myeloproliferative disorders: Summary of published literature and a perspective. 54 61
20425335 2006
110
High levels of circulating CD34 cells, dacrocytes, clonal hematopoiesis, and JAK2 mutation differentiate myelofibrosis with myeloid metaplasia from secondary myelofibrosis associated with pulmonary hypertension. 54 61
16418333 2006
111
Detection of the single hotspot mutation in the JH2 pseudokinase domain of Janus kinase 2 in bone marrow trephine biopsies derived from chronic myeloproliferative disorders. 54 61
16645202 2006
112
Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders. 54 61
16373657 2006
113
Respective clustering of unfavorable and favorable cytogenetic clones in myelofibrosis with myeloid metaplasia with homozygosity for JAK2(V617F) and response to erythropoietin therapy. 54 61
16532437 2006
114
Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications. 54 61
16673274 2006
115
New insights into the pathogenesis and drug treatment of myelofibrosis. 54 61
16456374 2006
116
V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis. 54 61
16293597 2006
117
Methods for the detection of the JAK2 V617F mutation in human myeloproliferative disorders. 54 61
16502590 2006
118
Chromosomal translocations in cancer and their relevance for therapy. 54 61
16357566 2006
119
Abnormalities of GATA-1 in megakaryocytes from patients with idiopathic myelofibrosis. 54 61
16127162 2005
120
Serum interleukin (IL)-1, IL-2, sIL-2Ra, IL-6 and thrombopoietin levels in patients with chronic myeloproliferative diseases. 54 61
16115126 2005
121
Genetics of myeloid malignancies: pathogenetic and clinical implications. 54 61
16155011 2005
122
The V617F JAK2 mutation and the myeloproliferative disorders. 54 61
16285006 2005
123
Involvement of transforming growth factor-beta and thrombopoietin in the pathogenesis of myelodysplastic syndrome with myelofibrosis. 54 61
16034467 2005
124
The JAK2V617F tyrosine kinase mutation in myeloproliferative disorders: status report and immediate implications for disease classification and diagnosis. 54 61
16007902 2005
125
Osteosclerosis in advanced chronic idiopathic myelofibrosis is associated with endothelial overexpression of osteoprotegerin. 54 61
15982347 2005
126
Peripheral T-cell lymphoma together with myelofibrosis with elevated plasma transforming growth factor-beta1. 54 61
16019489 2005
127
Role for the nuclear factor kappaB pathway in transforming growth factor-beta1 production in idiopathic myelofibrosis: possible relationship with FK506 binding protein 51 overexpression. 54 61
15833861 2005
128
Aberrant expression of transforming growth factor beta-1 (TGF beta-1) per se does not discriminate fibrotic from non-fibrotic chronic myeloproliferative disorders. 54 61
15726648 2005
129
Combined treatment with thalidomide, corticosteroids, and erythropoietin in patients with idiopathic myelofibrosis. 54 61
15693801 2005
130
Modern management of myelofibrosis. 54 61
15725078 2005
131
Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature. 54 61
15521916 2004
132
Osteosclerosis in idiopathic myelofibrosis is related to the overproduction of osteoprotegerin (OPG). 54 61
15504545 2004
133
Constitutively activated phosphatidylinositol 3-kinase primes platelets from patients with chronic myelogenous leukemia for thrombopoietin-induced aggregation. 54 61
15085152 2004
134
Reversal of bone marrow angiogenesis in chronic myeloid leukemia following imatinib mesylate (STI571) therapy. 54 61
14726401 2004
135
Thrombopoietin receptor (Mpl) expression by megakaryocytes in myeloproliferative disorders. 54 61
15095485 2004
136
Constitutive expression of the FK506 binding protein 51 (FKBP51) in bone marrow cells and megakaryocytes derived from idiopathic myelofibrosis and non-neoplastic haematopoiesis. 54 61
15089760 2004
137
Dysregulation and overexpression of HMGA2 in myelofibrosis with myeloid metaplasia. 54 61
14603445 2004
138
Imatinib mesylate in idiopathic and postpolycythemic myelofibrosis. 54 61
14635203 2003
139
Elevated plasma levels of TIMP-1 correlate with plasma suPAR/uPA in patients with chronic myeloproliferative disorders. 54 61
14667201 2003
140
Myelofibrosis with myeloid metaplasia. 54 61
14560783 2003
141
Sequential combination of thalidomide and erythropoietin determines transfusion independence and disease control in idiopathic myelofibrosis previously insensitive to both drugs used as single agents. 54 61
12886259 2003
142
Spontaneous STAT5 activation induces growth factor independence in idiopathic myelofibrosis: possible relationship with FKBP51 overexpression. 54 61
12842707 2003
143
Lack of alteration in GATA-1 expression in CD34+ hematopoietic progenitors from patients with idiopathic myelofibrosis. 54 61
12788793 2003
144
Bone marrow immunohistochemical studies of angiogenic cytokines and their receptors in myelofibrosis with myeloid metaplasia. 54 61
12648509 2003
145
Peripheral T-cell lymphoma presenting with rapidly progressing myelofibrosis. 54 61
12688359 2003
146
Mutational analysis of class III receptor tyrosine kinases (C-KIT, C-FMS, FLT3) in idiopathic myelofibrosis. 54 61
12580961 2003
147
Elevated thrombopoietin levels in patients with myelofibrosis may not be due to enhanced production of thrombopoietin by bone marrow. 54 61
12479847 2003
148
Overexpression of FKBP51 in idiopathic myelofibrosis regulates the growth factor independence of megakaryocyte progenitors. 54 61
12351405 2002
149
Overexpression of the polycythemia rubra vera-1 gene in essential thrombocythemia. 54 61
12377969 2002
150
Development of myelofibrosis in mice genetically impaired for GATA-1 expression (GATA-1(low) mice). 54 61
12149188 2002
151
Cytogenetic and molecular genetic aspects of idiopathic myelofibrosis. 54 61
12373082 2002
152
Comparative effects of interferon and hydroxyurea on bone marrow fibrosis in chronic myelogenous leukemia. 54 61
11697640 2001
153
Erythroleukemia following erythropoietin therapy, extramedullary hematopoiesis, and splenectomy in a patient with myelofibrosis and myeloid metaplasia. 54 61
11391725 2001
154
[The chronic Philadelphia chromosome-negative myeloproliferative syndrome I. Pathogenesis and pathophysiology]. 54 61
11379259 2001
155
Involvement of the fibrogenic cytokines, TGF-beta and bFGF, in the pathogenesis of idiopathic myelofibrosis. 54 61
11317961 2001
156
Bone marrow stromal cell distribution of basic fibroblast growth factor in chronic myeloid disorders. 54 61
11146571 2001
157
Bone marrow histochemical studies of fibrogenic cytokines and their receptors in myelodysplastic syndrome with myelofibrosis and related disorders. 54 61
11185990 2000
158
Matrix metalloproteinase and tissue inhibitor of metalloproteinase in human bone marrow tissues-an immunohistochemical study. 54 61
10938591 2000
159
Thrombopoietin activates the growth of megakaryoblasts in patients with chronic myeloproliferative disorders and myelodysplastic syndrome. 54 61
10776693 2000
160
Interferon alpha in the treatment of polycythemia vera. 54 61
10803930 2000
161
Effects of interferon and hydroxyurea on bone marrow fibrosis in chronic myelogenous leukaemia: a comparative retrospective multicentre histological and clinical study. 54 61
10651725 2000
162
Diagnosis and treatment of polycythemia vera and possible future study designs of the PVSG. 54 61
10674896 2000
163
The role of interferon-alpha in the treatment of idiopathic myelofibrosis. 54 61
10647876 1999
164
Dual implication of fibrogenic cytokines in the pathogenesis of fibrosis and myeloproliferation in myeloid metaplasia with myelofibrosis. 54 61
10550553 1999
165
PEG-rHuMGDF ameliorates thrombocytopenia in carboplatin-treated rats without inducing myelofibrosis. 54 61
10497847 1999
166
Autonomous megakaryocyte growth in essential thrombocythemia and idiopathic myelofibrosis is not related to a c-mpl mutation or to an autocrine stimulation by Mpl-L. 54 61
9864154 1999
167
Systemic transforming growth factor-beta in patients with bone marrow fibrosis--pathophysiological implications. 54 61
9766798 1998
168
Long term treatment of myeloproliferative disease with interferon-alpha-2b: feasibility and efficacy. 54 61
9740087 1998
169
rHuEpo for the treatment of anemia in myelofibrosis with myeloid metaplasia. Experience in 6 patients and meta-analytical approach. 54 61
9718866 1998
170
Major effects of TPO delivered by a single injection of a recombinant adenovirus on prevention of septicemia and anemia associated with myelosuppression in mice: risk of sustained expression inducing myelofibrosis due to immunosuppression. 54 61
9614574 1998
171
End-stage renal disease following polycythemia vera: in vitro and in vivo response of erythroid progenitors to erythropoietin and effects of sera on normal erythropoiesis. 54 61
9647492 1998
172
Effect of interferon-alpha therapy on bone marrow fibrosis in chronic myelogenous leukemia. 54 61
9436922 1998
173
Mpl ligand or thrombopoietin: biological activities. 54 61
9592015 1998
174
Myelofibrosis: experimental models and human studies. 54 61
11012187 1998
175
The role of transforming growth factor-beta in PEG-rHuMGDF-induced reversible myelofibrosis in rats. 54 61
9432016 1997
176
High thrombopoietin production by hematopoietic cells induces a fatal myeloproliferative syndrome in mice. 54 61
9373248 1997
177
The production of tissue inhibitors of metalloproteinases (TIMPs) in megakaryopoiesis: possible role of platelet- and megakaryocyte-derived TIMPs in bone marrow fibrosis. 54 61
9359522 1997
178
Elevated levels of basic fibroblast growth factor in megakaryocytes and platelets from patients with idiopathic myelofibrosis. 54 61
9163611 1997
179
Thrombopoietin-responsive essential thrombocythaemia with myelofibrosis. 54 61
9163612 1997
180
Combining interferon-alpha2b (IFN) and intravenous immunoglobulins IgG, IgM and IgA (IVIG) in rapid progressive myelofibrosis (MF) with Trisomy 1. 54 61
9092696 1997
181
Differential expression of transforming growth factor-beta, basic fibroblast growth factor, and their receptors in CD34+ hematopoietic progenitor cells from patients with myelofibrosis and myeloid metaplasia. 54 61
8977245 1996
182
Serum G-CSF levels in primary myelofibrosis and chronic neutrophilic leukemia as estimated by the highly sensitive chemiluminescence enzyme immunoassay (CLEIA). 54 61
8882966 1996
183
[Transformation of aplastic anemia to acute myeloid leukemia with myelofibrosis following treatment with granulocyte colony-stimulating factor and erythropoietin]. 54 61
8779784 1996
184
Investigation of calmodulin and basic fibroblast growth factor (bFGF) in idiopathic myelofibrosis: evidence for a role of extracellular calmodulin in fibroblast proliferation. 54 61
8703817 1996
185
Implication of CD44 in adhesion-mediated overproduction of TGF-beta and IL-1 in monocytes from patients with bone marrow fibrosis. 54 61
8611464 1996
186
Combination therapy with recombinant human erythropoietin, interferon-alpha-2b and granulocyte-macrophage colony-stimulating factor in idiopathic myelofibrosis. 54 61
8701705 1996
187
Expression of c-Mpl and c-Mpl ligand gene in hematopoietic cells of individuals with and without myeloproliferative disorders and leukemia cell lines. 54 61
8589367 1995
188
Leukemic transformation of primary myelofibrosis: immunophenotype, genotype and growth characteristics of blast cells. 54 61
8590852 1995
189
A new fibroblast growth stimulating activity from the human megakaryoblastic leukaemia cell line ELF-153: in vitro and in vivo findings. 54 61
7488550 1995
190
The effect of mast cell growth factor on peripheral blood granulocyte-macrophage colony-forming cells in methylcellulose in myeloproliferative disorders. 54 61
7589339 1995
191
Deposition of transforming growth factor-beta in the marrow in myelofibrosis, and the intracellular localization and secretion of TGF-beta by leukemic cells. 54 61
7741102 1995
192
The impact of interferon versus busulfan therapy on the reticulin stain-measured fibrosis in CML--a comparative morphometric study on sequential trephine biopsies. 54 61
7536475 1995
193
Recombinant human erythropoietin for the treatment of anemia in myelofibrosis with myeloid metaplasia. 54 61
7847335 1995
194
Detection and quantification of transforming growth factor beta (TGF-beta) and platelet-derived growth factor (PDGF) release by normal human megakaryocytes. 54 61
7869769 1995
195
Transforming growth factor-beta and megakaryocytes in the pathogenesis of idiopathic myelofibrosis. 54 61
7803262 1994
196
Recombinant human erythropoietin therapy in patients with myelofibrosis with myeloid metaplasia. 54 61
7918092 1994
197
Expression of the c-kit proto-oncogene in myeloproliferative disorders and myelodysplastic syndromes. 54 61
7512174 1994
198
Erythropoietin treatment of idiopathic myelofibrosis. 54 61
8175031 1993
199
Recombinant human erythropoietin in patients with myelodysplastic syndrome and myelofibrosis. 54 61
8285020 1993
200
[Evaluation of a one step sandwich enzymeimmunoassay for serum erythropoietin--serum erythropoietin values in polycythemia vera and related hematological disorders]. 54 61